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1 Introduction 
1.1 Breast Cancer 
Breast cancer is a disease of the mammary tissue. Luminal epithelial cells and basal 
or myoepithelial cells are the two major groups of differentiated cells which play an 
important role in this disease (Yamaguchi et al. 2009). Although many facts are 
known in respect of survival prognosis, a lack of information concerning the biology of 
this disease exists. Often breast cancer origins from a mutation in genes responsible 
for differentiation, cell growth or cell death. For better understanding of breast cancer 
genetic alterations are investigated constantly (Sørlie et al. 2001). 
In addition to pathological and clinical classification, breast cancer subtypes can be 
distinguished based upon gene expression data. The following subtypes are known: 
human epidermal growth factor receptor 2 (Her2/ ErbB2) -positive, normal breast-like, 
luminal (luminal A, luminal B and luminal C) and basal-like (basal A and basal B) type 
(Yamaguchi et al. 2009; Sørlie et al. 2001). About 15% to 25% of all breast cancer 
cells belong to the ErbB2-postive group. These cells exhibit either an amplification of 
the corresponding gene or a high production of the protein. It is also possible that 
both of these abnormalities can be found in these cancer cells. This aggressive 
subtype is not easy to treat and has a poor survival prognosis (Piccart-Gebhart et al. 
2005). Often there is a mutation in or a loss of the TP53 gene, which is responsible 
for an aggressive tumor and mostly leads to an early death. Sørlie and co-workers 
could show that 71% of the used ErbB2-positive cells had a mutation in the p53 gene 
(Sørlie et al. 2001). Like the ErbB2-positive breast cancer group, the normal-breast 
like cancer type is very aggressive with poor survival prognosis too. The normal-
breast like cancer cells have many characteristics in common with the basal-like 
cancer cells. This breast cancer subtype mostly is negative for the hormone 
receptors of estrogen and progesterone and for the Her2 receptor. Furthermore 
Sieuwerts and co-workers could show that the epithelial - mesenchymal transition 
markers TWIST1 and vimentin are highly produced in these cancer cells (Sieuwerts 
et al. 2009). In contrast to the normal-breast like cancer cells, almost all cells of the 
three luminal cancer subtypes are positive for the estrogen receptor α (Sotiriou et al. 
2003). Furthermore the luminal breast cancers are negative for the basal cytokeratins 
CK5, CK6, CK14, CK15, CK17, but they are positive for CK7, CK8, CK18 and CK19 
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(Laakso et al. 2006). The regulator protein GATA-3 plays an important role in luminal 
cell differentiation and can be used as predictive factor in luminal cancer cells 
(Kouros-Mehr et al. 2008). Expression properties of the subtype luminal A are for 
example GATA-3, ER-α, the tyrosine kinase c-kit, insulin-like growth factor-binding 
protein-3, cyclic AMP dependent transcription factor (ATF)-3, trefoil factor 3 and 
hepatocyte growth factor (Sotiriou et al. 2003; Sørlie et al. 2001). Sørlie and co-
workers could show that only 13% of the used luminal A breast cancer cells have a 
mutation in the TP53 gene. This seems to be a reason why this subtype is the one 
with the best survival prognosis compared to the others (Sørlie et al. 2001). Luminal 
B breast cancer cells do not have an overexpression of Her2, but they show a much 
higher proliferation leading to the worst survival prognosis of the three luminal 
subtypes (Sotiriou et al. 2003; Sørlie et al. 2001). Further characteristics of this 
subtype are for example the expression of tumor necrosis factor receptor-associated 
factor 3, Breast Cancer Antigen (BRCA) 1-associated protein 1 (BAP1), RAD21 and 
lower levels of vascular cell adhesion molecule 1 and ATF-3. The survival rate of the 
last subtype, luminal C, is somewhere in between luminal A and luminal B (Sotiriou et 
al. 2003). The fourth group of breast cancer is basal-like breast cancer, the focus of 
my diploma thesis.  
 
1.1.1 Basal-like breast cancer (BLBC) 
About 15% of all breast cancers are the basal-like breast cancer subtype (Bauer et 
al. 2007). This group of breast cancer is predominantly negative for the hormone 
receptors of estrogen and progesterone and for the receptor of Her2 (= triple 
negative). Some of the cancer cells with basal-like phenotype can be positive for one 
of the receptors (Cleator et al. 2007; Rakha et al. 2009). Although the triple-negative 
cancer cells and the BLBC are very similar, only 85% of the triple negatives are 
basal-like (Bauer et al. 2007). The basal-like breast cancer cannot be treated with 
Her2 neutralizing antibodies or anti-hormone therapy because of the lacking 
receptors (Cleator et al. 2007). These myoepithelial cells from the outer layer of the 
mammary duct are positive for the basal cytokeratins CK5, CK6, CK14 and CK17. 
Some of the cells are also positive for luminal cytokeratins like CK8 and CK18. 
Further characteristics of this high proliferating and thus very aggressive cancer type 
are for example high expression of vimentin, epidermal growth factor receptor 
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(EGFR), laminin, c-kit, nestin, P-cadherin and osteonectin. Caveolins 1 and 2, Ki-67, 
Sox2 and moesin are also produced in this high grad tumors. An overexpression of 
p53 is very common in basal-like cancer cells (Cleator et al. 2007; Rakha et al. 2009; 
Laakso et al. 2006). Studies have shown that about 82% of this cancer cells have a 
mutation within this protein or the corresponding gene (Sørlie et al. 2001; Cleator et 
al. 2007). Pathological investigations of BLBC pointed out that this cancer is adenoid 
cystic or metaplastic (typical or atypical medullary), high mitotic and has frequent 
apoptotic cells. In addition, central necrosis, vesicular chromatin, rarely stromal 
content and a high nuclear-cytoplasmic ratio could be discovered via these 
investigations (Cleator et al. 2007; Rakha et al. 2009). This basal-like group can be 
differentiated into two subtypes. The first subunit is characterized by high amounts of 
CDC2, topoisomerase IIα, matrix metalloproteinase 7, mitotic MAD2L1 and 
proliferation cell nuclear antigen. The characteristics of the second subgroup of the 
basal-like breast cancer are overproduction of caveolin 1 and 2, activating 
transcription factor 3, fos B, c-fos, c-jun, transforming growth factor β receptor II and 
hepatocyte growth factor (Cleator et al. 2007, Sotiriou et al. 2003). Genetic analyses 
showed that often no locus at 5q11 could be found in case of BLBC. This seems to 
be one reason why this cancer type counts to the aggressive ones. On this 
chromosome arm tumor suppressor genes and DNA-repair genes are normally 
found. It is known that the basal-like subtype shares many properties with BRCA1 
mutated breast cancer cells. The mutation or the loss of this gene responsible for 
homologous recombination often leads to incorrect repair and thus to the onset of 
cancer. The similarities of these two poor survival prognosticated cancer types are 
the high proliferation rate, the expression of the basal cytokeratins 5 and 6 and the 
EGFR. Further neither of them expresses the hormone receptor of estrogen (Cleator 
et al. 2007). Basal-like cancer cells seem to share characteristics with stem cells, 
such as expression of the stem cell regulatory genes CD133, Bmi1 and SLUG mRNA 
(Cleator et al. 2007, Storci et al. 2008). Visceral metastases of BLBC are often found 
in brain and lung and not in bone or lymph nodes, which is very often the case in 
other breast cancer types. It seems that the metastasis formation in basal-like breast 
cancer occurs in a different way compared to other breast cancer types (Rakha et al. 
2009). 
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1.2 Receptors 
1.2.1 Estrogen receptor (ER) 
The dimeric estrogen receptor, which is activated by binding 17β-estradiol, plays an 
important role in about 40% - 70% of breast cancer cells. These cells, which are 
dependent on estradiol, can be treated with anti-estrogens. The two different 
isoforms of this receptor ER-α and ER-β are known. The first one is the more 
important one in respect of breast cancer. Breast cancers which are negative for this 
receptor are difficult to treat. Often an overexpression of EGFR or Her2/neu can be 
seen in ER negative cancer cells (Boerner et al. 2005). 
 
1.2.2 Progesterone receptor (PR) 
This receptor belongs to the steroid hormone family of nuclear receptors and it can 
be distinguished between PR-α and PR-β. This receptor is activated by binding a 
steroid, for example progesterone. PR-α seems to be the receptor which plays an 
important role in breast cancer. Although a lot of this steroid is known, the entire role 
of progesterone in breast cancer is not defined yet (Richer et al. 2002). 
 
1.2.3 Human epidermal growth factor receptor (Her2/neu) 
Her2/neu (ErbB2) is a member of the ErbB-like oncogene family. Therefore it is 
related to the epidermal growth factor receptor and the receptor tyrosine kinases. 
Herceptin (Trastuzumab) is a monoclonal antibody used for treatment of those 20% - 
30% high-grade invasive breast cancer cells, which are overexpressing this receptor. 
The amount of this receptor plays an important role for survival and relapse time 
(Lakhani et al. 2002).  
 
1.2.4 Epidermal growth factor receptor (EGFR) 
The epidermal growth factor receptor (ErbB1) belongs to the ErbB family of 
receptors. This receptor as wells as the receptor Her2/neu mentioned above, are 
activated by dimerization (homo- or heterodimerization) after the ligand, for example 
EGF, has bound to the receptor. This receptor is likely to be expressed in a high 
amount in many breast cancer types. The consequence of this fact is more activation 
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of the Ras-Raf-MAPK pathway and the PI3K-Akt-mTOR pathway, leading to more 
proliferation of these cells (Anido et al. 2003). 
 
1.2.5 Further important proteins 
1.2.5.1 p53 
In about 30% of breast cancer cells this nuclear tumor suppressor is mutated, leading 
to a high activation of proliferation (Moll et al. 1992). The corresponding gene of the 
tetrameric protein is located on chromosome 17. This tumor suppressor often plays a 
role in the poor survival or relapse time of patients with breast cancer. Often no 
apoptosis can be induced with a mutated form of p53 (Bergh et al. 1995). 
 
1.2.5.2 Ki-67 
This protein is related to cellular proliferation and is also used as a proliferation 
marker in pathological diagnosis. The corresponding gene is located on the 
chromosome 10. It can be distinguished between two isoforms of this marker. Ki-67, 
which can be phosphorylated on one serine and one threonine, plays an important 
role in cell division. Furthermore a lot of this protein is present during mitosis. 
Cancers with a high amount of this proliferation marker have poor prognosis for 
survival. Breast cancer cells with mutated p53 express a higher amount of Ki-67, 
representing a higher proliferation rate. It seems that chemotherapy can work more 
efficient if there is a higher amount of Ki-67 in early breast cancer (Urruticoechea et 
al. 2005).  
 
1.2.5.3 Cytokeratin (CK) 5/6 
Cytokeratin 5/6 is a basal cytokeratin marker. It seems that this basal marker is 
associated with worse survival prognosis compared to luminal cytokeratin markers. 
CK5/6 often is found in invasive breast cancer (Abd El-Rehim et al. 2004). CK5/6 
serves as positive marker for basal-like breast cancer phenotype (Cheang et al. 
2008). 
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1.3 Cell lines 
1.3.1 Basal-like breast cancer cells 
Three different cell lines of this breast cancer subtype were used for the experiments 
(listed below). 
 
1.3.1.1 HCC-38 (CRL-2314) 
HCC-38 are adherent cells of the duct in the mammary gland. This cell line 
expresses Epithelial Glycoprotein 2 (EGP2) and cytokeratin 19. No receptors for the 
hormones of estrogen and progesterone are expressed. Further this cell line is 
negative for Her2/neu and positive for the protein p53 (http://www.lgcstandards-
atcc.org). The gene cluster of HCC-38 is basal B (Neve et al. 2006). To verify these 
data, pictures of the ER, PR, Her2/neu, EGFR, CK5/6, p53, Ki67 and HE were taken. 
The photos illustrated that HCC-38 are negative for ER, PR, Her2/neu and are 
positive for EGFR, p53, Ki-67 and CK5/6 (see Figure1). 
 
 
 
 
 
 
HE ER PR 
Her2/neu EGFR p53 
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Figure 1: Photos of receptors and proteins of HCC-38. Paraffin blocks were made with HCC-38 
followed by staining for HE, ER, PR, Her2/neu, EGFR, p53, Ki-67 and CK5/6. Legend: HE – 
Hematoxylin and Eosin; ER – estrogen receptor; PR – progesterone receptor, Her2/neu – human 
epidermal growth factor; EGFR – epidermal growth factor receptor; CK5/6 – cytokeratin 5/6. The 
pictures are kindly provided by Dr. Zsuzsanna Bagó-Horváth. 
 
1.3.1.2 HCC-1937 (CRL-2336) 
HCC-1937 are adherent cells of the duct in the mammary gland too. EGP2 and 
cytokeratin 19 are expressed in this cell line. Neither the estrogen receptor, nor the 
progesterone receptor, nor the p53 or the Her2/neu is produced in HCC-1937. 
Furthermore there is a mutation in the breast cancer 1 gene (BRCA1) 
(http://www.lgcstandards-atcc.org). The gene cluster of this cell line corresponds to 
the basal A type (Neve et al. 2006). Again, pictures of the different proteins and 
receptors of HCC-1937 were taken. The photos showed that this cell lines is negative 
for ER, PR, Her2/neu, p53 and CK5/6 and is positive for EGFR and Ki-67 (see Figure 
2). 
 
 
 
HE ER PR 
Her2/neu EGFR p53 
Ki-67 CK5/6 
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Figure 2: Photos of receptors and proteins of HCC-1937. Paraffin blocks were made with HCC-1937 
followed by staining for HE, ER, PR, Her2/neu, EGFR, p53, Ki-67 and CK5/6. Legend: HE – 
Hematoxylin and Eosin; ER – estrogen receptor; PR – progesterone receptor, Her2/neu – human 
epidermal growth factor; EGFR – epidermal growth factor receptor; CK5/6 – cytokeratin 5/6. The 
pictures are kindly provided by Dr. Zsuzsanna Bagó-Horváth. 
 
1.3.1.3 MDA-MB-231 (HTB-26) 
These are adherent cells of the mammary gland with an adenocarcinoma. MDA-MB-
231 cells are expressing the EGFR and the transforming growth factor receptor alpha 
(TGF alpha) (http://www.lgcstandards-atcc.org). Furthermore this cell line is negative 
for the receptors of estrogen, progesterone and Her2/neu and is positive for the 
protein p53. MDA-MB-231 belongs to the gene cluster basal B (Neve et al. 2006). 
Pictures were taken from this cell line too. The photos demonstrated that MDA-MB-
231 are negative for ER, PR, Her2/neu and CK5/6 and are positive for EGFR, p53 
and Ki-67 (see Figure 3). 
 
 
 
Ki-67 CK5/6 
HE ER PR 
Her2/neu EGFR p53 
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Figure 3: Photos of receptors and proteins of MDA-MB-231. Paraffin blocks were made with MDA-MB-
231 followed by staining for HE, ER, PR, Her2/neu, EGFR, p53, Ki-67 and CK5/6. Legend: HE – 
Hematoxylin and Eosin; ER – estrogen receptor; PR – progesterone receptor, Her2/neu – human 
epidermal growth factor; EGFR – epidermal growth factor receptor; CK5/6 – cytokeratin 5/6. The 
pictures are kindly provided by Dr. Zsuzsanna Bagó-Horváth. 
 
1.3.2 Reference breast cancer cells 
Three different breast cancer cells with epithelial, luminal or basal origin were used 
for the experiments (listed below). 
 
1.3.2.1 MCF-7 (HTB-22) 
MCF-7 are adherent cells of the mammary gland with an adenocarcinoma. This cell 
line is positive for the receptors of estrogen (http://www.lgcstandards-atcc.org) and 
progesterone and slightly positive for Her2/neu. The gene cluster of MCF-7 is luminal 
(Neve et al. 2006). Pictures of this cell line were taken too, to verify the data. Our 
data of the photos of MCF-7 illustrated that this cell line is negative for EGFR, CK5/6, 
p53 and Her2/neu and is positive for Ki-67, ER and PR (see Figure 4). 
 
 
Ki-67 CK5/6 
HE ER PR 
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Figure 4: Photos of receptors and proteins of MCF-7. Paraffin blocks were made with MCF-7 followed 
by staining for HE, ER, PR, Her2/neu, EGFR, p53, Ki-67 and CK5/6. Legend: HE – Hematoxylin and 
Eosin; ER – estrogen receptor; PR – progesterone receptor, Her2/neu – human epidermal growth 
factor; EGFR – epidermal growth factor receptor; CK5/6 – cytokeratin 5/6. The pictures are kindly 
provided by Dr. Zsuzsanna Bagó-Horváth. 
 
1.3.2.2 SKBR-3 (HTB-30) 
SKBR-3 are adherent cells of the mammary gland with an adenocarcinoma 
(http://www.lgcstandards-atcc.org). They are negative for the hormone receptors of 
estrogen and progesterone and are positive for Her2/neu. These cells belong to the 
epithelia gene cluster (Neve et al. 2006). Pictures of different receptors and proteins 
of this cell line were taken too. The photos demonstrated that SKBR-3 cells are 
positive for Her2/neu, p53, Ki-67 and EGFR and are negative for ER, PR and CK5/6 
(see Figure 5). 
 
 
Her2/neu EGFR p53 
Ki-67 CK5/6 
HE ER PR 
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Figure 5: Photos of receptors and proteins of SKBR-3. Paraffin blocks were made with SKBR-3 
followed by staining for HE, ER, PR, Her2/neu, EGFR, p53, Ki-67 and CK5/6. Legend: HE – 
Hematoxylin and Eosin; ER – estrogen receptor; PR – progesterone receptor, Her2/neu – human 
epidermal growth factor; EGFR – epidermal growth factor receptor; CK5/6 – cytokeratin 5/6. The 
pictures are kindly provided by Dr. Zsuzsanna Bagó-Horváth. 
  
1.3.2.3 MDA-MB-468 (HTB-132) 
The MDA-MB-468 are also adherent cells of the mammary gland with an 
adenocarcinoma. This cell line is positive for the EGFR and the TGF alpha 
(http://www.lgcstandards-atcc.org). The gene cluster of MDA-MB-468 is basal A and 
the cell line is negative for the hormone receptors of estrogen and progesterone. 
MDA-MB-468 is slightly positive for Her2/neu, which is the difference compared to 
the real basal-like breast cancer cells. Therefore this cell line has properties of both 
cancer types (Neve et al. 2006). Again, photos were taken. The photos showed that 
these cells are positive for p53, Ki-67, CK5/6 and EGFR and are negative for ER, PR 
andHer2/neu (see Figure 6). 
 
 
Her2/neu EGFR p53 
Ki-67 CK5/6 
HE ER PR 
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Figure 6: Photos of receptors and proteins of MDA-MB-468. Paraffin blocks were made with MDA-MB-
468 followed by staining for HE, ER, PR, Her2/neu, EGFR, p53, Ki-67 and CK5/6. Legend: HE – 
Hematoxylin and Eosin; ER – estrogen receptor; PR – progesterone receptor, Her2/neu – human 
epidermal growth factor; EGFR – epidermal growth factor receptor; CK5/6 – cytokeratin 5/6. The 
pictures are kindly provided by Dr. Zsuzsanna Bagó-Horváth. 
 
1.3.3 Overview of the used cancer cells 
The most important molecular characteristics of the three basal-like breast cancer 
cells and the three reference breast cancer cells are summarized in Table 1 below. 
 
Table 1: Characteristics of the used breast cancer cell lines. 
Cell lines Cluster ER PR Her2/neu EGFR p53 Ki-67 CK5/6 
HCC-38 basal B - - - + + + + 
HCC-1937 basal A - - - + - + - 
MDA-MB-231 basal B - - - + + + - 
MCF-7 luminal + + (-) - - + - 
SKBR-3 epithelial - - + + + + - 
MDA-MB-468 basal A - - (-) + + + + 
 
 
Her2/neu EGFR p53 
Ki-67 CK5/6 
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1.4 Y-box binding protein 1 (YB-1) 
The Y-box binding protein 1 is a member of the cold shock proteins family (Lasham 
et al. 2003). High amounts of this transcription and translation factor are found in 
73% of basal-like breast cancer cells. Stratford and co-workers could show that this 
protein can be activated by either the p90 ribosomal S6 kinase (RSK), or by activated 
Akt or by protein kinase C α (PKCα). This transcription factor is active after the 
phosphorylation of serine 102 (Stratford et al. 2008). YB-1 is located either in the 
nucleus or the cytoplasm. Normally, this protein is found in the cytoplasm. In 
particular during cellular stress, for example after the treatment with cytostatica, YB-1 
is translocated into the nucleus where it can work as transcription factor (Lage et al. 
2008). After activation of this protein, YB-1 can interact with EGFR, ER-α, Her-2 and 
c-MYC (Stratford et al. 2008; Lage et al. 2008). Stratford and co-workers could 
further show that YB-1 is mainly activated by RSK (which is activated via the mitogen 
activated protein kinase (MAPK) pathway). RSK1 is the more important kinase 
compared to RSK2 in relation to the YB-1 phosphorylation at serine 102 (Stratford et 
al. 2008). Phosphorylated YB-1 binds to the EGFR promoter in the nucleus and leads 
to a high expression of this receptor. Therefore the MAPK pathway is very active 
(Stratford et al. 2007). Experiments have shown that YB-1 negatively regulates the 
tumor suppressor p53. The more YB-1 is available, the less p53 can be active and 
vice versa (Lasham et al. 2003).  
 
1.5 Signaling pathways 
1.5.1 Mitogen activated protein kinase (MAPK) pathway 
The MAP kinases are serine/threonine kinases, which are activated by an 
extracellular stimulus. The stimulus is transduced via a signaling cascade from the 
surface into the nucleus. Three different major groups of theses kinases are 
classified in mammalian cells: 1) ERKs (extracellular signal-regulated kinases), 2) 
JNKs (c-Jun amino-terminal kinases) and 3) p38 MAPKs. All groups have a three-
tiered kinase cascade in common. This means that a MAPKKK activates a MAPKK, 
which further activates a MAPK (Johnson et al. 2002). For my diploma thesis, I 
focused on the ERK pathway. This pathway consists of Ras (G-protein), Raf 
(MAPKKK), MEK1/2 (MAPKK) and ERK1/2 (MAPK). After binding of the stimulus to 
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the receptor on the cell surface, the bound GDP of Ras is replaced by GTP. As a 
result this protein is activated. By binding this protein to Raf, Raf is converted into the 
active form too. Hence Raf is able to phosphorylate MEK1 and MEK2 at two different 
serine residues, leading to the activation of this kinase. The same two serines in 
MEK1 can also be phosphorylated by for example Tpl2, but to a much lower extent. 
ERK1/2, the last kinases in this cascade, can then be activated by either MEK1 or 
MEK2 by phosphorylation of threonine and tyrosine residues of the MAPK (Kolch 
2000). The MAPK can furthermore activate the p90 ribosomal S6 kinase (RSK), 
which then is able to activate the Y-box binding protein 1 via phosphorylation at the 
serine 102 (Stratford et al. 2008). The ERK pathway is needed for cell proliferation, 
cell survival, tumorigenesis, differentiation and development of the cells. Cancer cells 
often have mutations in proteins within this pathway, leading to a consistent 
activation of the ERK pathway and further to more proliferation of the cells. This leads 
to the assumption that anticancer drugs should downregulate this pathway (Johnson 
et al. 2002). 
 
1.5.2 Nuclear factor 'kappa-light-chain-enhancer' of activated 
B-cells(NF-κB) pathway 
This pathway can be distinguished between the canonical (NF-κB essential 
modulators (NEMO) dependent) and the non-canonical (NEMO independent) NF-κB 
signaling pathway. Recent studies led to the assumption that there occur more 
interactions between these two different pathways than it was always thought (Shih 
et al. 2011). Inflammation, immunity, apoptosis and cell proliferation are the 
processes which are triggered by the NF-κB pathway (Viatour et al. 2005). The 
transcription factor NF-κB can exist as homodimer or heterodimer of the Rel 
homology domain (RHD). These dimers can be built by five monomers (RelA, RelB, 
cRel, p50 and p52) (Shih et al. 2011). For my diploma thesis, the dimer RelA 
(p65):p50, which is part of the canonical way, was the most important one. At first the 
stimulus (e.g. TNF-α) binds to the corresponding receptor on the cell surface. This 
leads to the binding of some adaptors and the IκB kinase (IKK) complex to the 
receptor. The inhibitory molecule IκB-α is also bound to the IKK complex. After 
activation of this complex, the inhibitory molecule is at first phosphorylated, then 
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ubiquitinilated and at last degraded via the proteasome. After the depletion of this 
molecule, the p50:p65 complex can be phosphorylated and transduced into the 
nucleus. The NF-κB can bind the DNA in the unphosphorylated or in the 
phosphorylated state. In addition the whole NF-κB-IκB complex can be found either in 
the cytoplasm (mainly) or in the nucleus. The complex of adaptors, IKKs and IκB-α 
furthermore can activate Tpl2 (MAPKKK) to phosphorylate the p105 subunit, which 
then is ubiquitinilated and degraded. As a result free Tpl2 can further phosphorylate 
NF-κB (which then is transported into the nucleus) on the one hand, or activate the 
MAPKK, MEK1, on the other hand. This kinase in turn is able to activate ERK and 
then RSK, which again can phosphorylate NF-κB for example (Viatour et al. 2005). 
The NF-κB signaling pathway seems to play an important role in various cancer 
types. Often there is a mutation somewhere within this pathway, which leads to a 
permanent active transcription factor. This further leads to survival, invasion and 
metastasis of these cancer types. For example, basal-like breast cancer cells are 
cancer types, which usually show a high activity of this transcription factor 
(Yamaguchi et al. 2009). 
 
1.5.3 Phosphatidylinositol-3-kinase (PI3K) – Akt – mammalian 
target of Rapamycin (mTOR) pathway 
This signaling pathway is very important for the cells because it is necessary for 
many essential functions like cell proliferation, cell survival, cell differentiation 
transcription and translation (McAuliffe et al. 2010). After the binding of the stimulus 
to the receptor on the cell surface, the lipid kinase PI3K is activated and generates 
phosphatidylinositol-3,4,5-triphosphate (PI(3,4,5)P3) (PIP3) (Osaki et al. 2004). This 
leads to the activation of phosphoinositide-dependent kinase (PDK) 1, which causes 
the phosphorylation of Akt (also called Protein Kinase B (PKB)). The phosphorylated 
form of this serine/threonine kinase can activate mTOR, which is able either to 
activate Akt again via a feedback loop or phosphorylate the p70 S6 kinase (McAuliffe 
et al. 2010). Another possibility of active Akt is the phosphorylation of the IKK 
complex. This means that the serine/threonine kinase is able to activate the NF-κB 
pathway, leading to survival of the cells (Ozes et al. 1999). Further interactions of the 
PI3K-Akt-mTOR pathway with other pathways, for example the MAPK pathway, 
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seem to occur (Osaki et al. 2004). This pathway seems to play an important role in 
human cancer. Often the tumor suppressor gene phosphatase and tensin homolog 
(PTEN) is mutated or lost, leading to a permanently activated PI3K-Akt-mTOR 
pathway. This causes the proliferation and survival of cancer cells, for example of 
basal-like breast cancer cells (McAuliffe et al. 2010). 
 
1.5.4 Interactions of the signaling pathways 
After stimulation of one of the described pathways, this pathway is usually not the 
only activated one. There are some interactions between these signaling pathways 
which are known for sure and some which are assumed (Kolch 2000; Stratford et al. 
2008; Viatour et al. 2005; McAuliffe et al. 2010; Ozes et al. 1999; Osaki et al. 2004). 
Some of these interactions concerning the MAPK pathway, the PI3K-Akt-mTOR 
pathway and the NF-κB pathway are shown in Figure 7 below. 
 
Figure 7: Interactions of the MAPK pathway, the PI3K-Akt-mTOR pathway, the canonical NF-κB 
pathway and the Tpl2 dependent NF-κB pathway. Legend: The blue arrows stand for known 
interactions, the blue dotted arrows stand for interactions which are not known for sure. 
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1.6 Inhibitors 
1.6.1 Cetuximab (Erbitux) 
This substance is a mouse/human chimeric monoclonal antibody (IgG1) against the 
extracellular domain of the EGFR, which blocks the activation of the receptor tyrosine 
kinase. This inhibitor is often used for treatment of colon and breast cancer types with 
an overexpression of the EGF receptor. Xu and co-workers could further show that 
cetuximab is not effective if there is an overexpression of the EGFR on the one hand 
and an overexpression of, for example, Her2 on the other hand (Xu et al. 2005). 
 
1.6.2 PD98059 
PD98059 is an inhibitor of the mitogen activated protein kinase kinases, MEK1 and 
MEK2, and leads furthermore to no activation of the MAP kinases, ERK1 and ERK2. 
Monno and co-workers could show in their experiments that the level of 
phosphorylated ERK is reduced in MCF-7 cells after the treatment with this 
substance (Monno et al. 2000). 
 
1.6.3 U0126, U0124 
U0126 is an inhibitor of MEK1 and MEK2 without affecting ERK1, ERK2 or ATP. This 
substance is able to suppress the amount of active MAPK in MCF-7 cells, but not the 
total amount of the kinase (Kurokawa et al. 2000). U0124 is a negative control for 
U0126. 
 
1.6.4 ERK Inhibitor II (FR180204) 
This substance is an inhibitor of ERK1 and ERK2. Ohori and co-workers were able to 
show that this ERK Inhibitor can be used to treat mouse collagen-induced arthritis 
(CIA). A reduction of immune response can be achieved by inhibiting ERK with this 
substance (Ohori et al. 2007). 
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1.6.5 ERK Inhibitor III 
The phosphorylation of ERK1 and ERK2 is not affected by this inhibitor. This 
substance only avoids the phosphorylation of the ERK substrates RSK1 and Elk-1 via 
the EGF-stimulated pathway (http://www.emdchemicals.com). 
 
1.6.6 SL0101 
SL0101 is an inhibitor of the p90 ribosomal S6 kinase. In addition to this function, it 
also affects the proliferation of some cells. This substance does not have an effect on 
the survival of MCF-10A, a normal breast cancer cell line. The treatment of MCF-7 
with SL0101 leads to a suppression of their growth (Troussard et al. 2006). 
Furthermore this inhibitor leads to a lower amount of the phosphorylated protein    
YB-1S102, therefore a lower amount of YB-1 binding the promoter and thus leading to 
less production of the EGFR (Stratford et al. 2008). 
 
1.6.7 Akt Inhibitor IV 
This substance avoids the phosphorylation and therefore the activation of Akt. The 
binding of Akt Inhibitor IV instead of ATP occurs at a kinase upstream of Akt. No 
impact on the protein PI3 kinase of this substance could be detected 
(http://www.emdchemicals.com). 
 
1.6.8 Rapamycin 
Rapamycin is an inhibitor of the serine-threonine kinase mammalian target of 
rapamycin (mTOR). It leads to a suppression of the protein translation and to a 
disturbance of a proper cell cycle activity. Furthermore the phosphorylation of the p70 
S6 kinase and the 4E binding protein 1 cannot take place. Noh and co-workers could 
show that after the treatment with rapamycin, 12 out of 15 different breast cancer cell 
lines were not able to proliferate normally (Noh et al. 2004).  
 
1.6.9 Wortmannin 
This fungal metabolite is a selective, permeable and irreversible inhibitor of the 
catalytic activity of the PI3 kinase (Weng et al. 1999; Okada et al. 1994). The growth 
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of MCF-7 cells is suppressed in a similar way either by treatment of the cells with 
wortmannin or an overexpression of PTEN (Weng et al. 1999). 
 
1.6.10 PQ401 
PQ401 is a diaryl urea compound which binds at the kinase domain, the β-subunit, of 
the IGF1R. This substance leads to a blocking of the autophosphorylation of this 
receptor in MCF-7 cells and furthermore to no growth of these breast cancer cells. In 
addition, the treatment of MCF-7 breast cancer cells with PQ401 leads to more 
activation of the caspase. It seems that this substance induces the Akt antiapoptotic 
pathway after inhibiting the IGF1R (Gable et al. 2006). 
 
1.6.11 Violacein 
The purple-colored pigment violacein is obtained from the Chromobacterium 
violaceum, which is found in the Amazon in Brasil. This inhibitor plays a very 
important role in the treatment of cancer because of its antiviral, antibacterial, 
antitumoral, antileishmanial and antiulcerogenic effects. There are four known modes 
of actions of violacein, like the inhibition of the phosphorylation of IκB-α, less 
production of the two NF-κB subunits p50 and p65, blocking the NF-κB transport into 
the nucleus and at last a downregulation of the amount of phosphorylated Akt. These 
efficacies lead to the inhibition of cell growth and to an induction of apoptosis in colon 
cancer cells. Violacein does not only alter the activity of the NF-κB pathway, 
furthermore a suppression of the PI3-kinase–Akt–mTOR pathway can be observed. It 
seems that this pigment does not have an impact on the MAPK pathway (Kodach et 
al. 2006). 
 
1.6.12 Disulfiram 
This substance belongs to the dithiocarbamate family. This inhibitor can bind copper 
and the aldehyde dehydrogenase is suppressed by this substance (Chen et al. 
2006). Important characteristics of this antioxidant for the treatment of cancer are the 
altering of the redox potential and the blocking of reactive oxygen intermediates. The 
first feature of this substance leads to a downregulation of the amount of NF-κB 
which can bind the DNA in the nucleus. The other mentioned characteristic causes 
20 
 
the depletion of IκB-α (Wu et al. 2005). Furthermore disulfiram is used as substance 
for alcohol withdrawal (Chen et al. 2006). 
 
1.6.13 BAY 11-7082 
BAY 11-7082 is an inhibitor of the NF-κB pathway. This substance avoids the 
phosphorylation of IκB-α at the one hand and blocks the TNF-α-induced NF-κB 
activation on the other hand. It leads to apoptosis in colon cancer cells and therefore 
BAY 11-7082 plays an important role in treatment of this cancer type (Scaife et al. 
2002). 
 
1.6.14 MG-132 
This substance blocks the activity of the 26S proteasome (Morelli et al. 2003). MG-
132 treated MDA-MB-231 breast cancer cells have a reduced NF-κB binding activity. 
Furthermore this substance leads to less production of VEGF mRNA in MDA-MB-231 
(Shibata et al. 2002). 
 
1.6.15 Tpl2 Kinase Inhibitor 
The Tpl2 kinase exists in two isoforms and functions as an oncogene (Gantke et al. 
2011). It is a cell-permeable substance and inhibits the serine/threonine kinase Tpl2. 
The blocking of this kinase causes the suppression of the TNF-α production and the 
downregulation of signaling (Gavrin et al. 2005). 
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1.7 Objectives of my work 
Among the different subtypes of breast cancer, basal-like breast cancer shows 
particular characteristics. This cancer type is triple negative for the receptors 
estrogen, progesterone and Her2/neu. Thus, this carcinoma cannot be treated with 
anti-estrogens or Her2 neutralizing antibodies and is hardly susceptible to cytotoxic 
therapies (Cleator et al. 2007). Nevertheless, my laboratory could show previously 
that some cytotoxic compounds such as platinum derivates, taxanes and 
anthracyclines have effects on this subtype. In the last years research in tumor 
biology led to the assumption that signaling pathways and transcription factors may 
offer another option of treatment of this aggressive breast cancer (Johnson et al. 
2002; Yamaguchi et al. 2009; McAuliffe et al. 2010). 
 
The long-term objective of my work was to identify alternative therapies based on 
signaling pathways for this mamma carcinoma. This goal should be reached by 
identifying the key signaling pathways and transcription factors which are needed for 
the survival of these cancer cells. The used inhibitors are listed in Figure 8 below. For 
the experiments three basal-like breast cancer cells (HCC-38, HCC-1937, MDA-MB-
231) and three reference mamma carinomas (MCF-7, SKBR-3, MDA-MB-468) were 
used. 
 
Following methods were done: 
 Dose-response curves (MTT-assays) and adjustment via non-linear regression 
with inhibitors of different signaling pathways alone or in combination as well 
as in combination with cytotoxins (calculation of the IC50: inhibiting 
concentration of a substance for 50% of the cells). 
 Immunoblotting with cell lysates of inhibitor treated cell lines for quantitative 
analysis of the signaling pathways and the transcription factors. 
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Figure 8: Interactions of the MAPK pathway, the PI3K-Akt-mTOR pathway, the canonical NF-κB 
pathway and the Tpl2 dependent NF-κB pathway. Legend: The blue arrows stand for known 
interactions, the blue dotted arrows stand for interactions which are not known for sure. The red boxes 
are the used inhibitors. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Equipment 
Table 2: List of equipment used in this work. 
Device Device name  Supplier 
heating block Hybaid Omni Gene genXpress 
scale BP2100S Sartorius 
pH – meter PHM 83 Autocal Radiometer 
pH – electrode  Metrohm 
centrifuge 1  EBA 12 Hettich 
rotor 1 1412 Hettich 
centrifuge 2 Rotanta 46 RSC Hettich 
rotor 2 5624 Hettich 
vortexer L24 Labinco 
spectral photometer U-2900 Hitachi 
quartz cuvettes  Hellma 
X – ray films Amersham Hyperfilm® ECL GE Healthcare 
X – ray film cassette  Kodak 
developer  E.O.S. Agfa 
blotting apparatus TransBlot SD Cell Bio Rad 
PVDF – membrane   Thermo Scientific 
Whatman paper  Whatman 
SDS – Page apparatus MiniProtean Bio Rad 
1.5 ml tubes  Sarstedt 
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Device Device name  Supplier 
tips  Greiner bio – one 
sterile plugged tips  ART 
pipettor Pipetus® Hirschmann Laborgeräte 
pipettes  Costar 
cell scraper  Sarstedt 
magnetic stirrer M20/1 Framo Gerätetechnik 
incubator Cytoperm2 Heraeus 
laminar flow Maxisafe 2020 Thermo Scientific 
microscope 1 Nikon TMS Nikon 
microscope 2 BH-2 Olympus 
water bath  Memmert 
counting chamber Bürker – Türk  Marienfeld 
syringes  Gilson 
cryo tubes  Nalgene 
Asys Reader Asys Expert Plus Asys 
96 – well plates  Corning 
6 – well plates  Corning 
15 ml tubes  Corning 
50 ml tubes  Corning 
30 ml tubes Sterilin tubes Bertoni 
sonicator Microson XL 2000 Misonix 
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2.1.2 Cell lines 
Table 3: List of used cell lines. 
Cell line ATCC®number 
HCC-38 CRL-2314 
HCC-1937 CRL-2336 
MDA-MB-231 HTB-26 
MCF-7 HTB-22 
SKBR-3 HTB-30 
MDA-MB-468 HTB-132 
 
2.1.3 Materials for cell culture methods 
2.1.3.1 Reagents 
Table 4: List of used reagents in cell culture methods. 
Product Supplier 
RPMI 1640-Glutamax + L-glutamine Invitrogen 
Gentamycin Invitrogen 
Fetal calf serum (FCS) PAA 
Accutase PAA 
Trypsin PAA 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
Ethanol (100%) Merck 
Dye Solution Promega 
Solubilization Solution/ Stop Mix   Promega 
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2.1.3.2 Growth medium 
For all experiments the following growth medium was used. 
Table 5: Composition of used growth medium. 
Amount / Concentration Product 
500 ml RPMI 1640-Glutamax 
4 mM L-glutamine 
5 mg  Gentamycin 
10 % (heat inactivated) 
 stored at 4°C 
FCS 
 
 
2.1.3.3 Inhibitors and cytotoxins 
Table 6: List of used inhibitors and cytotoxins. 
Product Supplier Solvent 
Cetuximab cytotostatica pharmacy, AKH DMSO 
PD98059 Merck DMSO 
U0126 Merck DMSO 
U0124 Merck DMSO 
ERK Inhibitor II Merck DMSO 
ERK Inhibitor III Merck DMSO 
SL0101 Merck Ethanol 
PQ401 Tocris DMSO 
InSolution Akt Inhibitor IV® Merck DMSO 
Wortmannin Merck DMSO 
Rapamycin Merck DMSO 
Violacein Sigma-Aldrich DMSO 
Tetraethylthiuram disulfide (Disulfiram) Sigma-Aldrich DMSO 
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Product Supplier Solvent 
MG-132 Enzo Life Science DMSO 
Tpl2-Kinase Inhibitor Merck DMSO 
BAY 11-7082 Sigma-Aldrich DMSO 
Epirubicin cytotostatica pharmacy, AKH  
Docetaxel cytotostatica pharmacy, AKH  
Cisplatin cytotostatica pharmacy, AKH  
 
2.1.4 Materials for molecular biological methods 
2.1.4.1 Reagents 
Table 7: List of used reagents in molecular biological methods. 
Product Supplier 
Acrylamide/bis (97/3), 30 % Merck 
Ammonium peroxodisulfate (APS) Fluka 
Bromphenol blue Merck 
Complete Mini EDTA-free protease Inhibitor Cocktail Tablets Roche 
1,4 Dithiothreitol (DTT) Merck 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich 
Glacial acetic acid Merck 
Glycerol Merck 
Glycine Merck 
Potassium chloride  Merck 
Methanol Merck 
Sodium acetate Merck 
Sodium chloride Merck 
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Product Supplier 
Poinceau S Sigma-Aldrich 
PhosSTOP Phosphatase Inhibitor Cocktail Tablets Roche 
Phosphate bufferd saline (PBS) Invitrogen 
Sodiumdodecylsulfat (SDS) Pharmacia 
SuperSignal® West Dura Extended Duration Substrate Thermo Scientific 
SuperBlock® Blocking Buffer Thermo Scientific 
Temed Bio Rad 
Tris base Merck 
Tween-20 Merck 
NuPAGE® LDS Sample Buffer (4x) Invitrogen 
 
2.1.4.2 Antibodies and Markers 
Table 8: List of used markers, primary and secondary antibodies. 
Product Supplier Size (kDa) 
MagicMark™ XP Western Protein Standard Invitrogen  
Precision Plus Protein™ Dual Color Standards  Bio-Rad  
GAPDH (FL-335): sc-25778 Santa Cruz 37 
Rabbit monoclonal [EP2708Y] to YB1 (ab76149) Abcam 49 
Phospho-YB1 (Ser102) (C34A2) Rabbit mAb Cell Signaling 49 
RSK-2 (E-1): sc-9986 Santa Cruz 80 
IKK-α Cell Signaling 85 
IKK-β Cell Signaling 87 
phospho-IKK-α/β Cell Signaling 85/87 
NF-κBp65 Cell Signaling 65 
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Product Supplier Size (kDa) 
phospho-NF-κBp65 Cell Signaling 65 
IκB-α Cell Signaling 39 
phospho- IκB-α Cell Signaling 41 
MEK1/2 Cell Signaling 45 
Goat anti rabbit IgG HRPO (H+L) Pierce  
Goat anti mouse IgG HRPO (H+L) Pierce  
 
 
 
 
 
Figure 9: Used protein markers. (A) MagicMark
TM
 XP Western Protein Standard, (B) Precision Plus 
Protein
TM
 Dual Color Standards. 
 
2.1.4.3 Buffers 
All buffers were prepared after the Standard Operating Procedure of the laboratory. 
 
0.5 M Tris-HCl (pH 6.8) buffer 
Table 9: Chemical composition of 0.5 M Tris-HCl (pH 6.8) buffer.  
Concentration (Amount) Product/Supplier                             Storage 
0.5 M (6.05 g/ 100 ml ddH2O) Tris base (Merck)                                RT
 pH adjusted to 6.8 with HCl and sterile filtered   
 
A B 
30 
 
1 M Tris-HCl (pH 9.1) buffer 
Table 10: Chemical composition of 1 M Tris-HCl (pH 9.1) buffer. 
Concentration (Amount) Product/Supplier                             Storage 
1 M (12.1 g/ 100 ml ddH2O) Tris base (Merck)                                 RT
 pH adjusted to 9.1 with HCl and sterile filtered   
 
20% SDS buffer 
Table 11: Chemical composition of 20% SDS buffer. 
Concentration (Amount) Product/Supplier Storage 
20% (20 g/ 100 ml ddH2O) SDS (Pharmacia) RT 
 sterile filtered   
 
40% APS buffer 
Table 12: Chemical composition of 40% APS buffer. 
Concentration (Amount) Product/Supplier Storage 
40% (400 mg/ 1 ml ddH2O) APS (Fluka) -20°C 
 
5x Tris-Glycine (pH 8.3) buffer 
Table 13: Chemical composition of 5x Tris-Glycine (pH 8.3) buffer. 
Concentration (Amount) Product/Supplier Storage 
125 mM (15.1 g/1 l ddH2O) Tris base (Merck) RT 
1250 mM (94 g/ 1 l ddH2O) Glycine (Merck)  
0.5% (50 ml/ 1 l ddH2O) 10% SDS 
(Pharmacia) 
 
 pH adjusted to 8.3 with HCl and sterile 
filtered  
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Transfer buffer  
Table 14: Chemical composition of Transfer buffer. 
Concentration (Amount) Product/Supplier Storage 
39 mM (2.9 g/1 l ddH2O) Glycine (Merck) 4°C 
48 mM (5.8 g/ 1 l ddH2O) Tris base (Merck)  
0.037% (3.7 ml/ 1 l ddH2O) 10% SDS (Pharmacia)  
20% (200 ml/ 1 l ddH2O) Methanol (Merck)  
 sterile filtered  
 
2x SDS-lysis buffer (non-denaturing) 
Table 15: Chemical composition of 2x SDS-lysis buffer (non-denaturing). 
Concentration 
(Amount) 
Product/Supplier  Storage 
50 mM  
(1 ml/10 ml ddH2O) 
0.5 M Tris-HCl pH 6.8 -20°C 
6% (3 ml/ 10 ml ddH2O) 20% SDS (Pharmacia)  
20% (2 ml/ 10 ml ddH2O) 100% Glycerol (Merck)  
1.85 mM  
(37 µl/ 10 ml ddH2O) 
0.5 M EDTA (Sigma-Aldrich)  
1 Tablet PhosSTOP Phosphatase Inhibitor Cocktail 
(Roche) 
 
1 Tablet Complete Mini EDTA-free Protease Inhibitor 
Cocktail (Roche) 
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10x Tris buffered saline (TBS) (pH 7.4) buffer 
Table 16: Chemical composition of 10x Tris buffered saline (TBS) (pH 7.4) buffer. 
Concentration (Amount) Product/Supplier  Storage 
136.9 mM (80 g/1 l ddH2O) Sodium chloride (Merck) RT 
5.4 mM (4 g/ 1 l ddH2O) Potassium chloride (Merck)  
49.5 mM (60 g/ 1 l ddH2O) Tris base (Merck)  
 pH adjusted to 7.4 with HCl and 
sterile filtered 
  
 
0.5% Glacial acetic acid solution 
Table 17: Chemical composition of 0.5% Glacial acetic acid solution. 
Concentration (Amount) Product/Supplier Storage 
5% (5 ml/100 ml ddH2O) Glacial acetic acid (Merck) RT 
 
0.1% Poinceau S solution  
Table 18: Chemical composition of 0.1% Poinceau S solution. 
Concentration (Amount) Product/Supplier Storage 
0.1% (0.1 g/100 ml ddH2O) 5% Glacial acetic acid RT 
 sterile filtered, reusable 
 
2x probe buffer (denaturing) 
Table 19: Chemical composition of 2x probe buffer (denaturing). 
Concentration (Amount) Product/Supplier Storage 
72 mM (100 mg/10 ml ddH2O) DTT (Merck) -20°C 
5 ml  100% Glycerol (Merck)  
1 pipette tip Bromphenol blue (Merck)  
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2.2 Methods 
2.2.1 Cell culture methods 
2.2.1.1 Cell Proliferation Assay 
The CellTiter 96® Non-Radioactive Cell Proliferation Assay (MTT-Assay [3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]) was performed to determine 
the dose-response relationship in the used cellular systems. 
 
 harvesting and counting cells 
At first the growth medium was discarded and Accutase was added for 8 minutes at 
37°C, 5% CO2:95% air to detach the cells. After harvesting the cells they were 
centrifuged at 287 g for 5 minutes at room temperature. Then the cells were counted 
using Bürker-Türk counting chambers to reach the amount of 104 cells in 100 µl per 
well in a 96-well microtiterplate. All experiments were performed in triplicates. 
 
 serial dilution of inhibitors/ cytotoxin 
A serial dilution was made with the used inhibitors and cytotoxins. 25 µl of the 
substances were mixed with the cells in the 96-well plate (no inhibitors/ cytotoxins in 
well A, increasing inhibitor/ cytotoxin concentration from well B to H). Growth medium 
was added into the wells to reach the end volume of 150 µl. The microtiterplates 
were put into the incubator (37°C, 5% CO2:95% air) for 72 hours. 
Following inhibitor/cytotoxin concentrations were used for the experiments (see Table 
20). 
 
Table 20: Concentration range and incubation time of used substances. 
Substance Concentration range Incubation time 
Rapamycin 0.1 nM - 100 µM 72 h 
Cetuximab 0.01 ng/ml – 10 µg/ml 72 h 
Violacein 1 nM – 1 mM 72 h 
Akt Inhibitor IV 0.01 nM – 10 µM 72 h 
Wortmannin 0.1 nM – 0.1 mM 72 h 
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Substance Concentration range Incubation time 
Disulfiram 4 nM – 4 mM 72 h 
SL0101 0.1 nM – 0.1 mM 72 h 
PQ401 0.1 nM – 0.1 mM 72 h 
ERK Inhibitor II 0.1 nM – 0.1 mM 72 h 
ERK Inhibitor III 0.1 nM – 0.1 mM 72 h 
PD98059 0.1 nM – 0.1 mM 72 h 
U0126 0.1 nM – 0.1 mM 72 h 
U0124 0.1 nM – 0.1 mM 72 h 
Tpl2 Kinase Inhibitor 0.1 pM – 0.1 µM 72 h 
BAY 11-7082 0.1 nM – 0.1 mM 72 h 
MG-132 0.1 nM – 0.1 mM 72 h 
Akt Inhibitor IV + Rapamycin 0.01 µM – 0.1 µM (A) + 
1 µM – 10 µM (R) 
72 h 
Akt Inhibitor IV + Violacein 0.01 µM – 0.1 µM (A) + 
0.1 nM – 1 nM (V) 
72 h 
Akt Inhibitor IV + Wortmannin 0.01 µM – 0.1 µM (A) + 
0.01 µM + 1 µM (W) 
72 h 
PD98059 + ERK Inhibitor II 0.1 µM + 10 µM (P) + 
1 µM – 10 µM (E) 
72 h 
ERK Inhibitor II + SL0101 1 µM – 10 µM (E) + 
1 µM – 10 µM (S) 
72 h 
Wortmannin + ERK Inhibitor II 0.01 µM - 1 µM (W) + 
1 µM – 10 µM (E) 
72 h 
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Substance Concentration range Incubation time 
Akt Inhibitor IV + PD98059 0.01 µM – 0.1 µM (A) + 
0.1 µM – 10 µM (P) 
72 h 
Akt Inhibitor IV + ERK Inhibitor II 0.01 µM – 0.1 µM (A) + 
1 µM – 10 µM (E) 
72 h 
Akt Inhibitor IV + SL0101 0.01 µM – 0.1 µM (A) + 
1 µM – 10 µM (S) 
72 h 
PD98059 + Wortmannin 0.1 µM – 10 µM (P) + 
0.01 µM - 1 µM (W) 
72 h 
PD98059 + Violacein 0.1 µM – 10 µM (P) + 
0.1 nM – 1 nM (V) 
72 h 
Epirubicin + Akt Inhibitor IV 0.1 nM – 0.1 µM (E) + 
0.01 µM – 0.1 µM (A) 
72 h 
Epirubicin + Violacein 0.1 nM – 0.1 µM (E) + 
0.1 nM – 1 nM (V) 
72 h 
Epirubicin + PD98059 0.1 nM – 0.1 µM (E) + 
0.1 µM – 10 µM (P) 
72 h 
Epirubicin + Wortmannin 0.1 nM – 0.1 µM (E) + 
0.01 µM - 1 µM (W) 
72 h 
Docetaxel + Akt Inhibitor IV 0.01 nM – 10 nM (D) + 
0.01 µM – 0.1 µM (A) 
72 h 
Docetaxel + Violacein 0.01 nM – 10 nM (D) + 
0.1 nM – 1 nM (V) 
72 h 
Docetaxel + Wortmannin 0.01 nM – 10 nM (D) + 72 h 
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Substance Concentration range Incubation time 
0.01 µM - 1 µM (W) 
Docetaxel + PD98059 0.01 nM – 10 nM (D) + 
0.1 µM – 10 µM (P) 
72 h 
Cisplatin + Akt Inhibitor IV 0.01 µM – 10 µM (C) + 
0.01 µM – 0.1 µM (A) 
72 h 
Cisplatin + Violacein 0.01 µM – 10 µM (C) + 
0.1 nM – 1 nM (V) 
72 h 
Cisplatin + Wortmannin 0.01 µM – 10 µM (C) + 
0.01 µM - 1 µM (W) 
72 h 
Cisplatin + PD98059 0.01 µM – 10 µM (C) + 
0.1 µM – 10 µM (P) 
72 h 
Violacein + Tpl2 Kinase Inhibitor 0.1 nM – 1 nM (V) + 
0.1 nM – 1 nM (T) 
72 h 
Violacein + BAY 11-7082 0.1 nM – 1 nM (V) + 
0.01 µM – 1µM (B) 
72 h 
Violacein + MG-132 0.1 nM – 1 nM (V) + 
1 nM – 10 nM (M) 
72 h 
BAY 11-7082 + Tpl2 Kinase Inhibitor 0.01 µM – 1µM (B) + 
0.1 nM – 1 nM (T) 
72 h 
BAY 11-7082 + MG-132 0.01 µM – 1µM (B) + 
1 nM – 10 nM (M) 
72 h 
MG-132 + Tpl2 Kinase Inhibitor 1 nM – 10 nM (M) + 
0.1 nM – 1 nM (T) 
72 h 
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 addition of dye solution and solubilizer 
The viable cells were counted indirectly by performing the MTT-Assay, to assess the 
cytotoxicity of the used inhibitors/ cytotoxins. 15 µl of a dye solution, a chromogenic 
dye which contains a tetrazolium salt, were added into each well of the 
microtiterplate. The plate was incubated (37°C, 5% CO2:95% air) for 4 hours. The 
living cells are uptaking the tetrazolium salt into the mitochondria and are converting 
it into a formazan product. After the incubation time 100 µl of the solubilizer were 
added into each well to dissolve the formazan. 
 
 detection and evaluation 
After 24 hours the extinction of the wells of the microtiterplates were measured using 
Anthos–Reader 2001. The wavelength of 570 nm and a reference wavelength of 690 
nm were chosen to detect the amount of the produced, blue-coloured, formazan. The 
evaluation was done by drawing sigmoid nonlinear dose-response curves using 
GraphPadPrism 4.0 software. The IC50 value – the inhibitor/ cytotoxin concentration 
leading to 50% growth inhibition compared to untreated cells – was calculated by this 
program. 
 
2.2.1.2 Inhibition of cells for cell lysates 
The used cell lines were inhibited with different substances to prepare cell lysates for 
Western blotting. 
 
 harvesting and counting cells 
The cells were harvested and counted like written in 2.2.1.1 harvesting and counting 
cells. A cell count of 3x 104 cells in 1 ml per well of a 6-well plate was requested in 
this approach. 
 
 addition of inhibitors 
The concentrations of the inhibitors were chosen very low, that the majority of the 
cells were still viable. The inhibitors were diluted until the requested concentration 
was reached. 1.5 ml of the solution was added into each well of the plate. The 6-well 
plates were put into the incubator (37°C, 5% CO2:95% air) for 72 hours. 
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2.2.2 Molecular biological methods 
2.2.2.1 Western blotting 
All steps were performed after the Standard Operating Procedure of the laboratory. 
 
 cell lysis 
All steps for cell lysis were done on ice. The growth medium was discarded and the 
cells were washed twice with cold 1x PBS. 20 µl/ 50 µl 2x SDS-lysis buffer were put 
onto the cells in the 6-well plate/ cell flask. The cells were detached by using cell 
scrapers and transferred into 1.5 ml tubes. 
 
 sonication 
For the complete lysis of the cells and the degradation of genomic DNA, the cells 
were sonicated. The sonicater was setted in pulsed mode and approximately 30 
pulses were given to the cell lysates. This procedure was done until the lysates were 
homogeneous. 
 
 spectral photometry 
A 1:100 dilution of the probes with ddH20 were made and 500 µl of the dilution were 
measured against the blank at 260 nm. The amount of protein was calculated with 
the following formula: Extinction 0.1 µg = 1.3 µg/µl protein. 
 
 electrophoresis 
The SDS-PAGE-gel was prepared like written in the tables below. 
 
 10% separating gel: 
Table 21: Chemical composition of 10% separating gel. 
Reagents For one gel For two gels 
Acrylamide/bis (97/3) 30% 1.5 ml 3 ml 
ddH2O 1.5 ml 3 ml 
1 M Tris-HCl (pH 9.1) 1.9 ml 3.8 ml 
10% SDS 50 µl 100 µl 
40% APS 10 µl 20 µl 
Temed 2.5 µl 5 µl 
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The gel apparatures were filled with the separating gel and a 1:2 dilution of 
isopropanol with ddH2O was put on top of the gel. After one hour the separating gel 
was compact. 
 
 4% stacking gel: 
Table 22: Chemical composition of 4% stacking gel. 
Reagents For one gel For two gels 
Acrylamide/bis (97/3) 30% 0.325 ml 0.65 ml 
ddH2O 0.625 ml 1.25 ml 
0.5 M Tris-HCl (pH 6.8) 1.55 ml 3.1 ml 
10% SDS 25 µl 50 µl 
40% APS 4 µl 8 µl 
Temed 2.5 µl 5 µl 
 
The isopropanol/ddH20 mixture was removed and the stacking gel was put on top of 
the separation gel. The combs were put into the gel and after 30 minutes of 
polymerization the combs were removed. 
10 µg of protein and 4x loading buffer were substituted with 1x Tris-glycine-buffer to 
reach the end volume of 20 µl. The probes were denatured at 100°C for 3 minutes, 
kept on ice and then centrifuged for some seconds. Then the whole volume of the 
probes and 2.5 µl of the markers were loaded onto the gel. The used buffer for 
electrophoresis was 1x Tris-glycine-buffer and the gel was running at 150 Volt for 
about one hour. 
 
 transfer 
For the transfer of the proteins from the gel onto the membrane a semi-dry blotting 
method was used. 3 transfer buffer conditioned Whatman papers were put onto the 
positive electrode. The methanol and transfer buffer conditioned membrane was then 
put onto the papers. Onto the membrane the conditioned gel was put afterwards. At 
the top 3 transfer buffer conditioned Whatman papers were put. At last the negative 
electrode was put onto them. 
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 Assembly: 
  
 
 
 
Figure10: Assembly of protein transfer. 
 
For transfer following conditions were chosen: 0.8 mA/ cm2 membrane, 1 hour. 
 
 Poinceau S staining 
As a control, if the transfer did work, the membrane was washed 3 times with ddH20. 
Afterwards Poinceau S solution was put onto the membrane for 2-3 minutes. The 
membrane was washed again with ddH20 for two times. Now the transferred protein 
bands were visible. 
 
 blocking 
At first all binding sites on the membrane were blocked with 15 ml SuperBlock 
Blocking Buffer + 0.05% Tween 20 at 4°C over night. 
 
 primary antibody 
The primary antibody was diluted in SuperBlock Blocking Buffer + 0.05% Tween 20. 
The antibodies were diluted like written in the instruction leaflet and are listed in 
Table 23 below. 15 ml of diluted primary antibody was put onto the membrane for 
one hour at room temperature. The membrane was gently shaking this hour. 
 
Table 23: Used primary antibody dilutions. 
Primary antibody Dilution 
GAPDH 1:5000 
YB-1 1:10000 
phospho-YB-1S102 1:1000 
cathode (negative) 
 3x Whatman papers 
gel 
membrane 
3x Whatman papers 
anode (positive) 
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Primary antibody Dilution 
RSK-2 1:100 
IKK-α 1:1000 
IKK-β 1:1000 
phospho-IKK-α/β 1:1000 
NF-κBp65 1:1000 
phospho-NF-κBp65 1:1000 
IκB-α 1:1000 
phospho- IκB-α 1:1000 
MEK1/2 1:1000 
 
 washing 
The used washing buffer was 1x TBS (pH 7.4) + 0.05% Tween 20. The membrane 
was washed 5 times for 10 minutes with this buffer at room temperature. The 
membrane was gently shaking the whole time. 
 
 secondary antibody 
The stock concentration of the secondary antibodies (0.8 mg/ml) were diluted with 
SuperBlock Blocking Buffer + 0.05% Tween 20 to reach the end concentration of 
1:100000 to 1:250000 (see Table 24). 15 ml of diluted secondary antibody was put 
onto the membrane for one hour at room temperature. The membrane was gently 
shaking this hour. 
 
Table 24: Used secondary antibody dilutions. 
Secondary antibody  Dilution 
Goat anti rabbit IgG HRPO (H+L) 1:200000 
Goat anti mouse IgG HRPO (H+L) 1:100000 
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 washing 
The used washing buffer was 1x TBS (pH 7.4) + 0.05% Tween 20. The membrane 
was washed 5 times for 10 minutes with this buffer at room temperature. The 
membrane was gently shaking the whole time. 
 
 development 
For development of the protein bands Luminol/Enhancer Solution and Stable 
Peroxidase Solution were mixed in ratio 1:1. 0.125 ml/cm2 membrane were put onto 
the membrane and incubated at room temperature for 5 minutes. The membrane was 
gently shaking the whole time. The membrane was dried between two Whatman 
papers and put into a plastic foil. The foil was put into a film cassette and an X-ray 
film was put onto the membrane for seconds to minutes until the protein bands were 
visible. The X-ray film was put into the developer. For orientation of the size of the 
protein bands, the bands of the markers were titled with their sizes. 
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3 Results 
3.1 Cytotoxicity Assays 
3.1.1 Cytotoxicity assays of one inhibitor 
These experiments were done to establish the IC50 value, the concentration inhibiting 
50% of the exposed cells. For the experimental procedure see chapter 2.2.1.1.  
 
Cetuximab 
 
This antibody against the extracellular domain of the EGFR should inhibit the 
activation of the receptor tyrosine kinase (Xu et al. 2005). In our approach, cetuximab 
showed no activity in the investigated cell lines. The IC50 values were calculated with 
more than10 µg/ml for the BLBC and the reference cells (see Figure 11). 
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Figure 11: Cytotoxicity assay of Cetuximab. The BLBC and the reference cells were treated with 0.01 
ng/ml – 10 µg/ml Cetuximab and incubated for 72 h at 37°C. Legend: BLBC: basal-like breast cancer 
cells, ext.570: extinction at a wavelength of 570 nm, conc. [µg/ml]: concentration of the substance in 
µg per one ml, tit.: titrated. 
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Rapamycin, SL0101, ERK Inhibitor II, ERK Inhibitor III, U0126 
 
MEK1/2, ERK1/2, RSK and mTOR were blocked with the corresponding inhibitors, 
for further investigation of the MAPK pathway. Rapamycin had little activity in the 
BLBC up to concentrations of 10 µM, but inhibited cells significantly at 100 µM. The 
same effect could be observed in the ERK Inhibitor II treated reference lines and in 
all six cell lines treated with SL0101, ERK Inhibitor III and U0126 (except U0126 
treated HCC-38). A minor activity was reached in rapamycin treated reference cell 
lines with continuous killing of the cells. No significant killing of the BLBC up to 
concentrations of 100 µM could be observed after treatment with ERK Inhibitor II (see 
Figure 12). 
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BLBC, ERK Inhibitor II tit.
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BLBC, ERK-Inhibitor III tit.
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BLBC, U0126 tit.
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Figure 12: Cytotoxicity assay rapamycin, SL0101, ERK Inhibitor II, ERK Inhibitor III and U0126. The 
BLBC and the reference cells were treated with 0.1 nM–100 µM rapamycin, 0.1 nM–0.1 mM SL0101, 
0.1 nM–0.1 mM ERK Inhibitor II, 0.1 nM–0.1 mM ERK Inhibitor III, 0.1 nM–0.1 mM U0126 and 
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incubated for 72 h at 37°C. Legend: BLBC: basal-like breast cancer cells, ext.570: extinction at a 
wavelength of 570 nm, conc. [µM]: concentration of the substance in µM, tit.: titrated. 
 
None of the used inhibitors of the MAPK pathway was able to kill the breast cancer 
cells at low concentrations. There was no significant difference between the BLBC 
and the reference lines. 
 
Wortmannin 
 
This metabolite acts as inhibitor of the catalytic activity of PI3 kinase (Weng et al. 
1999; Okada et al. 1994). In the used cellular systems, little activity of wortmannin 
could be observed in the BLBC up to concentrations of 10 µM. A more significant 
inhibition could be reached at a concentration of 100 µM. The reference cell lines 
could be inhibited significantly with a wortmannin concentration of 10 µM (see Figure 
13). 
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HCC-38 Wortmannin tit.
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Figure 13: Cytotoxicity assay of wortmannin. The BLBC and the reference cells were treated with 0.1 
nM–0.1 mM wortmannin and incubated for 72 h at 37°C. Legend: BLBC: basal-like breast cancer cells, 
ext.570: extinction at a wavelength of 570 nm, conc. [µM]: concentration of the substance in µM, 
conc., tit.: titrated. 
 
Disulfiram 
 
The two known modes of action of this substance are the NF-κB suppression and the 
IκB-α inhibition (Chen et al. 2006). Although the obtained data points were very 
fluctuating and the slopes of the investigated cell lines were very different, disulfiram 
seemed to show an inhibitory effect on all six breast cancer cell lines. The IC50 value 
was observed, using low or very low micromolar concentrations of this substance 
(see Table 25).  
 
Table 25: Calculated IC50 values of the used cell lines inhibited with disulfiram. 
Cell lines IC50 
HCC-38 8.86 µM 
HCC-1937 0.3 µM 
MDA-MB-231 0.39 µM 
MCF-7 0.71 µM 
SKBR-3 7.58 µM 
MDA-MB-468 0.29 µM 
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No significant difference could be observed between the basal-like breast cancer 
cells and the reference cells (see Figure 14). 
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Figure 14: Cytotoxicity assay of disulfiram. The BLBC and the reference cells were treated with 4 nM–
4 mM disulfiram and incubated for 72 h at 37°C. Legend: BLBC: basal-like breast cancer cells, 
ext.570: extinction at a wavelength of 570 nm, conc. [µM]: concentration of the substance in µM, tit.: 
titrated. 
 
Akt Inhibitor IV 
 
The substance Akt Inhibitor IV prevents the autophosphorylation of Akt 
(http://www.emdchemicals.com). In the used cellular systems 50% inhibition of the 
cells could be reached at very low micromolar concentrations by the use of Akt 
Inhibitor IV (see Table 26).  
 
Table 26: Calculated IC50 values of the used cell lines inhibited with Akt Inhibitor IV. 
Cell lines  IC50 
HCC-38 0.95 µM 
HCC-1937 0.9 µM 
MDA-MB-231 0.64 µM 
MCF-7 0.77 µM 
SKBR-3 0.46 µM 
MDA-MB-468 0.25 µM 
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The activity of this substance was almost the same in all six breast cancer cell lines 
(see Figure 15). 
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Figure 15: Cytotoxicity assay of Akt Inhibitor IV. The BLBC and the reference cells were treated with 
0.01 nM – 0.01 mM Akt Inhibitor IV and incubated for 72 h at 37°C. Legend: BLBC: basal-like breast 
cancer cells, ext.570: extinction at a wavelength of 570 nm, conc. [µM]: concentration of the substance 
in µM, tit.: titrated. 
 
In comparison to rapamycin, the other used inhibitor of the PI3K-Akt-mTOR pathway, 
Akt Inhibitor IV was able to inhibit the cell growth at lower concentrations. 
 
Violacein 
 
The purple-colored pigment violacein has four known modes of actions (inhibition of 
the phosphorylation of IκB-α, reduced production of the two NF-κB subunits p50 and 
p65, blocking the NF-κB transport into the nucleus) (Kodach et al. 2006). In addition, 
violacein inhibits the PI3-kinase–Akt–mTOR pathway. In our cellular systems, 
violacein has shown high activity in all cell lines. IC50 values at very low micromolar 
or even at nanomolar concentrations were observed (see Table 27). 
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Table 27: Calculated IC50 values of the used cell lines inhibited with violacein. 
Cell lines IC50 (average out of 2 experiments) 
HCC-38 0.59 µM 
HCC-1937 75 nM 
MDA-MB-231 0.51 µM 
MCF-7 38 nM 
SKBR-3 0.125 µM 
MDA-MB-468 0.11 µM 
 
There was no significant difference between BLBC and the reference breast cancer 
cell line (one experiment out of two is shown) (see Figure 16). 
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Figure 16: Cytotoxicity assay of violacein. The BLBC and the reference cells were treated with 1 nM–1 
mM violacein and incubated for 72 h at 37°C. Legend: BLBC: basal-like breast cancer cells, ext.570: 
extinction at a wavelength of 570 nm, conc. [µM]: concentration of the substance in µM, tit.: titrated. 
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BAY 11-7082 
 
This substance functions as an inhibitor of the phosphorylation of IκB-α and the 
suppression of NF- κB activation (Scaife et al. 2002). The IC50 value was observed at 
low micromolar concentrations in the breast cancer cells by the use of BAY 11-7082 
(see Table 28).  
 
Table 28: Calculated IC50 value of the used cell lines inhibited with BAY 11-7082. 
Cell lines IC50 (average out of 2 experiments) 
HCC-38 1.495 µM 
HCC-1937 3.405 µM 
MDA-MB-231 0.17 µM 
MCF-7 1.64 µM 
SKBR-3 2.645 µM 
MDA-MB-468 1.51 µM 
 
Again, no significant difference between the BLBC and the reference breast cancer 
cell lines was observed (one experiment out of two is shown) (see Figure 17). 
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Figure 17: Cytotoxicity assay of BAY 11-7082. The BLBC and the reference cells were treated with 0.1 
nM – 0.1 mM BAY 11-7082 and incubated for 72 h at 37°C. Legend: BLBC: basal-like breast cancer 
cells, ext.570: extinction at a wavelength of 570 nm, conc. [µM]: concentration of the substance in µM, 
tit.: titrated. 
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MG-132 
 
This proteasome inhibitor was tested too, for further investigations of the NF-κB 
pathway. A growth inhibition of all used breast cancer cell lines was observed at very 
low micromolar concentrations by the use of MG-132 (see Table 29). 
 
Table 29: Calculated IC50 value of the used cell lines inhibited with MG-132. 
Cell lines IC50 (average out of 2 experiments) 
HCC-38 0.18 µM 
HCC-1937 0.14 µM 
MDA-MB-231 0.26 µM 
MCF-7 0.485 µM 
SKBR-3 0.145 µM 
MDA-MB-468 0.13 µM 
 
The six breast cancer cell lines were reacting very similar after the addition of this 
inhibitor (one experiment out of two is shown) (see Figure 18). 
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Figure 18: Cytotoxicity assay of MG-132. The BLBC and the reference cells were treated with 0.1 nM–
0.1 mM MG-132 and incubated for 72 h at 37°C. Legend: BLBC: basal-like breast cancer cells, 
ext.570: extinction at a wavelength of 570 nm, conc. [µM]: concentration of the substance in µM, tit.: 
titrated. 
 
The activity of MG-132 was similar to the other used NF-κB inhibitors BAY 11-7082 
and violacein. 
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Tpl2 Kinase Inhibitor 
 
This inhibitor suppresses the activity of the kinase Tpl2 (Gavrin et al. 2005). The IC50 
value in the BLBC and the reference cells was observed at nanomolar concentrations 
of Tpl2 Kinase Inhibitor (see Table 30). In contrast to all the other substances 
(disulfiram, Akt Inhibitor IV, violacein, BAY 11-7082, MG-132; Figures 14-18), a 
complete eradication of the cells at higher concentrations was not obtained in any of 
the used cells. In this case a growth arrest could be obtained in all six cell lines. 
 
Table 30: Calculated IC50 value of the used cell lines inhibited with Tpl2 Kinase Inhibitor. 
Cell lines  IC50 (average out of 2 experiments) 
HCC-38 55.5 nM 
HCC-1937 25.5 nM 
MDA-MB-231 45.5 nM 
MCF-7 21.5 nM 
SKBR-3 28.5 nM 
MDA-MB-468 13.5 nM 
 
Similar activity of Tpl2 Kinase Inhibitor was observed in the six breast cancer cell 
lines (one experiment out of two is shown) (see Figure 19). 
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Figure 19: Cytotoxicity assay of Tpl2 Kinase Inhibitor. The BLBC and the reference cells were treated 
with 0.1 pM – 0.1 µM Tpl2 Kinase Inhibitor and incubated for 72 h at 37°C. Legend: BLBC: basal-like 
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breast cancer cells, ext.570: extinction at a wavelength of 570 nm, conc. [µM]: concentration of the 
substance in µM, tit.: titrated. 
 
Tpl2 Kinase Inhibitor was the NF-κB pathway inhibitor with the most activity in the 
used cellular systems. 
 
Cytotoxicity assays with the substances PD98059, U0124 and PQ401 were done too. 
No or no significant activity of this substance could be reached (data not shown). 
 
3.1.2 Cytotoxicity assays of two inhibitors or one inhibitor and 
one cytotoxin combination 
These experiments were done to find out if lower IC50 values could be reached when 
combinations of two inhibitors or one inhibitor and one cytotoxin were used. Two 
concentrations of each inhibitor/ cytotoxin were chosen for these approaches. The 
higher one represents the concentration at which the substance alone was barely 
working in the cell lines. The lower concentration was chosen a power of ten below 
the higher one, in case the inhibition starts earlier if combinations of two substances 
were used. For the experimental procedure see chapter 2.2.1.1. Instead of 
calculating the IC50 value with the GraphPadPrism 4.0 software, a bar diagram was 
made out of the data, which were obtained from the Anthos Reader apparatus. 
 
Akt Inhibitor IV + Violacein 
 
The combination of Akt Inhibitor IV (inhibitor of Akt phosphorylation) and violacein 
(multiple mode of action inhibitor of NF-κB pathway) led to an earlier inhibition of the 
reference cell lines (MCF-7, SKBR-3 and MDA-MB-468) at the higher concentrations, 
compared to the single use of these two substances. Unfortunately this effect could 
not be seen in the basal-like breast cancer cell lines (HCC-38, HCC-1937, MDA-MB-
231) (see Figure 20). 
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Figure 20: Cytotoxicity assay of Akt Inhibitor IV and violacein. The cell lines were treated with the two 
inhibitors and incubated for 72 h at 37°C. Legend: ΔE(570nm): extinction at a wavelength of 570 nm, 
conc. [µM]: concentration of the substances in µM, Akt Inhibitor IV L: 0.01 µM (all cell lines), Akt 
Inhibitor IV H: 0.1 µM (all cell lines), violacein L: 0.0001 µM (all cell lines), violacein H: 0.001 µM (all 
cell lines), Combination L: 0.01 µM Akt Inhibitor IV + 0.0001 µM violacein (all cell lines), Combination 
H: 0.1 µM Akt Inhibitor IV + 0.001 µM violacein (all cell lines). 
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For further investigations of the communication between the pathways, more 
combinations with different inhibitors of the three pathways (MAPK pathway, PI3K-
Akt-mTOR pathway, NF-κB pathway) and cytotoxins were done. Unfortunately no 
higher activity in the used cellular systems was observed by these combinations. The 
following substances were combined in a concentration range of 0.0001 µM to 10 µM 
(data not shown). 
 
 Akt Inhibitor IV + rapamycin   Akt Inhibitor IV + wortmannin 
 ERK Inhibitor II + PD98059   ERK Inhibitor II + SL0101 
 ERK Inhibitor II + wortmannin   Akt Inhibitor IV + PD98059 
 Akt Inhibitor IV + ERK Inhibitor II  Akt Inhibitor IV + SL0101 
 PD98059 + wortmannin   PD98059 + violacein 
 Epirubicin + PD98059    Epirubicin + Akt Inhibitor IV 
 Epirubicin + wortmannin   Epirubicin + violacein 
 Docetaxel + PD98059    Docetaxel + Akt Inhibitor IV 
 Docetaxel + wortmannin   Docetaxel + violacein 
 Cisplatinum + PD98059   Cisplatinum + Akt Inhibitor IV 
 Cisplatinum + wortmannin   Cisplatinum + violacein 
 violacein + Tpl2 Kinase Inhibitor  violacein + BAY 11-7082 
 violacein + MG-132    BAY 11-7082 + Tpl2 Kinase Inhibitor 
 BAY 11-7082 + MG-132    MG-132 + Tpl2 Kinase Inhibitor 
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3.2 Quantitative Analysis of Proteins 
The same secondary antibodies and one or both of the markers listed in table were 
used for all Western blotting experiments. GAPDH was chosen as loading control. 
For experimental procedure see chapter see 2.2.2.1.  
 
3.2.1 Quantitative analysis of YB-1, phospho-YB-1
S102
 and 
RSK2 in untreated breast cancer cells 
With the first experiments I wanted to find out if there is a difference in the amount of 
the transcription factor YB-1, the active form of this transcription factor,  
phospho-YB-1S102, and the protein RSK2 in the untreated used breast cancer cells.  
  
 
 
 
 
 
 
 
 
 
 
   
Figure 21: Detection of the proteins YB-1, phospho-YB-1
S102
, RSK2 and GAPDH. 10 µg of the cell 
lines were used for a 10% SDS-Page gel and transferred onto a PVDF-membrane. The first antibody 
was diluted in SuperBlock Blocking Buffer 1:10000 for YB-1, 1:1000 for phospho-YB-1
S102
, 1:100 for 
RSK2 and 1:5000 for GAPDH. GAPDH, YB-1 and phospho-YB-1
S102
 were incubated with Goat anti 
rabbit IgG (H+L) HRPO and RSK2 with Goat anti mouse IgG (H+L) HRPO. As exposure time 1 minute 
for YB-1 and GAPDH, 10 minutes for RSK2 and 30 minutes for phospho-YB-1
S102
 were chosen. 
 
There was no difference in the level of YB-1 in the untreated breast cancer cells. A 
higher amount of the phosphorylated form of this transcription factor was observed in 
the cell lines HCC-1937, SKBR-3 and MCF-7 (lanes 4-6). Due to the fact that the 
antibody against phospho-YB-1S102 showed unspecific binding (lanes 2-3) and thus 
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was not very informative; the detection of this protein was not reproducible and was 
therefore not done in the following experiments. Furthermore it seemed that 
untreated HCC-38 expressed more RSK2 protein compared to the other untreated 
cell lines.  
 
3.2.2 Quantitative analysis of YB-1 and RSK2 in inhibitor 
treated breast cancer cells 
The following experiments were done to find out if the treatment of the cells with 
different inhibitors, from which it was supposed that they could have an effect on the 
proteins YB-1 and RSK2, alters the amount of their expression compared to the 
untreated cells. The concentrations of the inhibitors were chosen very low that only a 
small amount of the cells were killed. 
 
3.2.2.1 Akt Inhibitor IV treated cells 
 
 
 
 
 
 
 
 
 
 
Figure 22: Detection of the proteins YB-1, RSK2 and GAPDH. 10 µg of the cell lines were used for a 
10% SDS-Page gel and transferred onto a PVDF-membrane. The first antibody was diluted in 
SuperBlock Blocking Buffer 1:10000 for YB-1, 1:100 for RSK2 and 1:5000 for GAPDH. GAPDH and 
YB-1 were incubated with Goat anti rabbit IgG (H+L) HRPO and RSK2 with Goat anti mouse IgG 
(H+L) HRPO. As exposure time 10 seconds for YB-1, 10 minutes for GAPDH and 5 minutes for RSK2 
were chosen (45´ for HCC-38 – incubated at a different blot).  
 
The basal-like breast cancer cells (HCC-38, HCC-1937, MDA-MB-231) were 
expressing less YB-1 protein compared with the reference cells (MCF-7, SKBR-3, 
MDA-MB-468) and the untreated cells after the treatment with Akt Inhibitor IV (see 
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Figure 21). The signal of the RSK2 band seemed to be a little less intense in HCC-38 
compared to the others. Maybe this was due to the fact that this cell line was done on 
a separate gel, which in general produced weak signals. More RSK2 protein was 
produced by HCC-1937 compared to all other treated cells. No difference in the 
amount of this protein in the untreated and the Akt Inhibitor IV treated cells was 
observed (see Figure 21).  
 
3.2.2.2 Violacein treated cells 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Detection of the proteins YB-1, RSK2 and GAPDH. 10 µg of the cell lines were used for a 
10% SDS-Page gel and transferred onto a PVDF-membrane. The first antibody was diluted in 
SuperBlock Blocking Buffer 1:10000 for YB-1, 1:100 for RSK2 and 1:5000 for GAPDH. GAPDH and 
YB-1 were incubated with Goat anti rabbit IgG (H+L) HRPO and RSK2 with Goat anti mouse IgG 
(H+L) HRPO. As exposure time 10 seconds for YB-1, 10 minutes for GAPDH and 45 minutes for 
RSK2 were chosen. 
 
It seemed that the treatment with violacein did not influence the expression of YB-1 
compared with the untreated cells (see Figure 21). The bands of RSK2 were very 
weak in all cell lines, especially in MCF-7 and MDA-MB-468. In MDA-MB-468 there 
was almost no signal visible. Maybe the production of this protein was downregulated 
after the treatment with violacein in comparison to the untreated ones (see Figure 
21).  
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3.2.2.3 Disulfiram treated cells 
 
 
 
 
 
 
 
 
        
Figure 24: Detection of the proteins YB-1, RSK2 and GAPDH. 10 µg of the cell lines were used for a 
10% SDS-Page gel and transferred onto a PVDF-membrane. The first antibody was diluted in 
SuperBlock Blocking Buffer 1:10000 for YB-1, 1:100 for RSK2 and 1:5000 for GAPDH. GAPDH and 
YB-1 were incubated with Goat anti rabbit IgG (H+L) HRPO and RSK2 with Goat anti mouse IgG 
(H+L) HRPO. As exposure time 10 seconds for YB-1, 1 minute for GAPDH and 3 minutes for RSK2 
were chosen. No MDA-MB-468 was incubated with GAPDH. 
 
Due to the lack of cell lysate from MDA-MB-468, no loading control with GAPDH 
could be done with this cell line. The treatment with disulfiram did not influence the 
amount of produced YB-1 compared with the untreated cells (see Figure 21). HCC-
1937 was producing more RSK2 and HCC-38 as well as MDA-MB-468 were 
producing less RSK2 compared with the other cell lines and the untreated ones (see 
Figure 21). 
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3.2.3 Quantitative analysis of NF-κB pathway members in 
untreated breast cancer cells 
With the first experiment I wanted to find out if there is a difference in the amount of 
NF-κB pathway proteins in the untreated basal-like breast cancer cells and the 
untreated reference breast cancer cells.  
 
 
 
 
 
 
  
 
 
        
 
 
 
 
Figure 25: Detection of the proteins NF-κBp65, phospho-NF-κBp65, IκB-α, phospho-IκB-α and 
GAPDH. 10 µg of the cell lines were used for a 10% SDS-Page gel and transferred onto a PVDF-
membrane. The first antibody was diluted in SuperBlock Blocking Buffer 1:1000 for NF-κBp65, 
phospho-NF-κBp65, IκB-α, phospho-IκB-α and 1:5000 for GAPDH. GAPDH, NF-κBp65, phospho-NF-
κBp65 and phospho-IκB-α were incubated with Goat anti rabbit IgG (H+L) HRPO and IκB-α with Goat 
anti mouse IgG (H+L) HRPO. As exposure time 15 seconds for IκB-α, 1 minute for GAPDH, 5 minutes 
for phospho-NF-κBp65 and 40 minutes for NF-κBp65 and phospho-IκB-αwere chosen.  
 
The basal-like breast cancer cells expressed much more phoshporylated as well as 
unphosphorylated NF-κBp65 than the reference cells. After 5 minutes there was no 
phospho-NF-κBp65 signal visible in the cell line MDA-MB-468, but a weak signal 
could be seen after 40 minutes (data not shown). Much more IκB-α was present in 
HCC-38 and HCC-1937 than in the other cells. Only a weak signal could be seen in 
MDA-MB-468. The amount of the phosphorylated form of IκB-α was almost the same 
in all cells (maybe a little bit more in HCC-1937). The band of MDA-MB-468 
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incubated with GAPDH was less intense because less than 10 µg lysate were 
loaded. The antibodies IKK-α, IKK-β and phospho-IKK-α/β were used as well but no 
informative results could be obtained (data not shown).  
 
3.2.4 Quantitative analysis of NF-κB pathway members in 
inhibitor treated breast cancer cells 
These experiments were done to find out if the inhibitors, which had a suppressive 
effect on the cells in the cytotoxicity assays (see Figures 15-19), alter the cells on 
protein level as well compared to the untreated state. Again the concentrations of the 
inhibitors were chosen very low that only a small amount of cells were killed by the 
substances. 
 
3.2.4.1 Violacein treated cells 
 
 
 
 
 
           
 
 
 
 
 
 
 
     
Figure 26: Detection of the proteins NF-κBp65, phospho-NF-κBp65, IκB-α, phospho-IκB-α and 
GAPDH. 10 µg of the cell lines (inhibited with 1 nM violacein) were used for a 10% SDS-Page gel and 
transferred onto a PVDF-membrane. The first antibody was diluted in SuperBlock Blocking Buffer 
1:1000 for NF-κBp65, phospho-NF-κBp65, IκB-α, phospho-IκB-α and 1:5000 for GAPDH. GAPDH, 
NF-κBp65, phospho-NF-κBp65 and phospho-IκB-α were incubated with Goat anti rabbit IgG (H+L) 
HRPO and IκB-α with Goat anti mouse IgG (H+L) HRPO. As exposure time15 seconds for IκB-α, 5 
M
a
g
ic
 M
a
rk
 
H
C
C
-3
8
 
M
D
A
-M
B
-2
3
1
 
H
C
C
-1
9
3
7
 
S
K
B
R
-3
 
M
C
F
-7
 
M
D
A
-M
B
-4
6
8
 
P
re
c
is
io
n
 P
lu
s
  
GAPDH      
(5´) 
phospho-IκB-α      
(40´) 
IκB-α      
(15´´) 
phospho-NF-κBp65 
(5´) 
NF-κBp65 
(40´) 
75 kDa  
 
40 kDa  
 
40 kDa  
 
37 kDa 
25 kDa 
80 kDa  
60 kDa 
 
100 kDa        
80 kDa 
 
37 kDa  
 
37 kDa  
 
40 kDa  
 
63 
 
minutes for phospho-NF-κBp65 and GAPDH and 40 minutes for NF-κBp65 and phospho-IκB-α were 
chosen.  
 
The inhibition with violacein led to a much weaker signal of NF-κBp65 in the basal-
like breast cancer cells. The signal in the reference cells stayed almost the same as 
in the untreated cells (see Figure 25). The phosphorylated NF-κBp65 was only 
downregulated in the cell line MDA-MB-231, maybe a little in MCF-7 as well. SKBR-3 
and MDA-MB-231 were producing less IκB-α compared with the untreated state (see 
Figure 25). The amount of phospho-IκB-α protein was less in all cell lines in 
comparison with the untreated cells (see Figure 25). In this Blot HCC-38 and MDA-
MB-468 had a weaker GAPDH signal than they normally had. 
 
3.2.4.2 Tpl2 Kinase Inhibitor treated cells 
 
 
 
 
 
 
 
                   
 
 
 
       
 
 
Figure 27: Detection of the proteins NF-κBp65, phospho-NF-κBp65, IκB-α, pospho-IκB-α and GAPDH. 
10 µg of the cell lines (inhibited with 1 nM Tpl2 Kinase Inhibitor) were used for a 10% SDS-Page gel 
and transferred onto a PVDF-membrane. The first antibody was diluted in SuperBlock Blocking Buffer 
1:1000 for NF-κBp65, phospho-NF-κBp65, IκB-α, phospho-IκB-α and 1:5000 for GAPDH. GAPDH, 
NF-κBp65, phospho-NF-κBp65 and phospho-IκB-α were incubated with Goat anti rabbit IgG (H+L) 
HRPO and IκB-α with Goat anti mouse IgG (H+L) HRPO. As exposure time 15 seconds for IκB-α, 1 
minute for GAPDH, 5 minutes for phospho-NF-κBp65 and NF-κBp65 and 40 minutes for phospho-IκB-
α were chosen.  
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Compared with the untreated control, the treatment with Tpl2 Kinase Inhibitor did not 
alter the amount of NF-κBp65 in the cell lines very much (see Figure 25). Maybe a 
little more protein was expressed in the reference cell lines and in MDA-MB-231. 
MCF-7 and MDA-MB-231 were producing less phospho-NF-κBp65, MDA-MB-468 
seemed to be expressing a little more of this protein compared with the untreated 
cells (see Figure 25). HCC-38 and MDA-MB-468 were producing less phospho-IκB-α 
compared with the untreated state (see Figure 25). No difference in the IκB-α signal 
could be seen in the cell lines after the treatment with Tpl2 Kinase Inhibitor (see 
Figure 25). 
 
3.2.4.3 MG-132 treated cells 
 
 
 
 
 
 
     
 
 
 
 
 
     
Figure 28: Detection of the proteins NF-κBp65, phospho-NF-κBp65, IκB-α, phospho-IκB-α and 
GAPDH. 10 µg of the cell lines (inhibited with 0.01 µM MG-132) were used for a 10% SDS-Page gel 
and transferred onto a PVDF-membrane. The first antibody was diluted in SuperBlock Blocking Buffer 
1:1000 for NF-κBp65, phospho-NF-κBp65, IκB-α, phospho-IκB-α and 1:5000 for GAPDH. GAPDH, 
NF-κBp65, phospho-NF-κBp65 and phospho-IκB-α were incubated with Goat anti rabbit IgG (H+L) 
HRPO and IκB-α with Goat anti mouse IgG (H+L) HRPO. As exposure time 15 seconds for IκB-α, 1 
minute for GAPDH, 5 minutes for  phospho-NF-κBp65 and phospho-IκB-α and 40 minutes for NF-
κBp65 were chosen.  
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It seemed that the inhibition with MG-132 led to a weaker NF-κBp65 expression, 
except in HCC-38 in comparison with the untreated cells (see Figure 25). The signal 
of the phosphorylated NF-κBp65 was weaker in all cell lines too, except in MDA-MB-
468 with a higher expression of this protein. Compared with untreated controls, the 
IκB-α signal was downregulated in all cell lines, except in MDA-MB-468 where it was 
upregulated (see Figure 25). A downregulation of phospho-IκB-α in all breast cancer 
cell lines was observed after treatment with MG-132 when compared with untreated 
controls (see Figure 25). 
 
3.2.4.4 BAY 11-7082 treated cells 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Detection of the proteins NF-κBp65, phospho-NF-κBp65, IκB-α and phospho-IκB-α. 10 µg 
of the cell lines (inhibited with 0.1 µM BAY 11-7082 (HCC-38, SKBR-3 1 µM)) were used for a 10% 
SDS-Page gel and transferred onto a PVDF-membrane. The first antibody was diluted in SuperBlock 
Blocking Buffer 1:1000 for NF-κBp65, phospho-NF-κBp65, IκB-α and phospho-IκB-α. NF-κBp65, 
phospho-NF-κBp65 and phospho-IκB-α were incubated with Goat anti rabbit IgG (H+L) HRPO and 
IκB-α with Goat anti mouse IgG (H+L) HRPO. As exposure time 15 seconds for IκB-α, and 40 minutes 
for NF-κBp65, phospho-NF-κBp65 and phospho-IκB-α were chosen.  
 
In the basal-like breast cancer cell lines less NF-κBp65 was expressed after the 
treatment with BAY 11-7082. In the reference cell lines the amount increased, except 
in MCF-7. Phospho-NF-κBp65 was downregulated in MDA-MB-231, MCF-7 as well 
as SKBR-3 and upregulated in MDA-MB-468 compared with the untreated cells (see 
Figure 25). In HCC-38 and HCC-1937 the amount of the protein stayed the same. 
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The treatment of the cells with this inhibitor did not alter the protein level of 
unphosphorylated and phosphorylated IκB-α compared with the untreated control 
(see Figure 25). GAPDH could not be blotted due to technical problems. 
 
3.2.4.5 Akt Inhibitor IV treated cells 
 
 
 
 
 
 
 
      
 
 
 
    
 
      
Figure 30: Detection of the proteins NF-κBp65, phospho-NF-κBp65, IκB-α, phospho-IκB-α and 
GAPDH. 10 µg of the cell lines (inhibited with 0.1 µM Akt Inhibitor IV (SKBR-3, MDA-MB-468 0.01 
µM)) were used for a 10% SDS-Page gel and transferred onto a PVDF-membrane. The first antibody 
was diluted in SuperBlock Blocking Buffer 1:1000 for NF-κBp65, phospho-NF-κBp65, IκB-α, phospho-
IκB-α and 1:5000 for GAPDH. GAPDH, NF-κBp65, phospho-NF-κBp65 and phospho-IκB-α were 
incubated with Goat anti rabbit IgG (H+L) HRPO and IκB-α with Goat anti mouse IgG (H+L) HRPO. As 
exposure time 15 seconds for IκB-α, 5 minutes for phospho-IκB-α and and 40 minutes for NF-κBp65, 
phospho-NF-κBp65 and GAPDH were chosen.  
 
After the inhibition with Akt Inhibitor IV all basal-like breast cancer cell lines were 
producing less NF-κBp65 compared with the untreated cells (see Figure 25). SKBR-3 
was slightly upregulating and MCF-7 was slightly downregulating the protein. In 
MDA-MB-468 the amount of NF-κBp65 stayed the same. While all cell lines express 
less phospho-NF-κBp65, in MDA-MB-468 more of this protein was present compared 
with the untreated control (see Figure 25). The expression of IκB-α was lower in all 
cells except in MDA-MB-468 after the treatment with this inhibitor. In comparison with 
M
a
g
ic
 M
a
rk
 
H
C
C
-3
8
 
M
D
A
-M
B
-2
3
1
 
H
C
C
-1
9
3
7
 
S
K
B
R
-3
 
M
C
F
-7
 
M
D
A
-M
B
-4
6
8
 
P
re
c
is
io
n
 P
lu
s
  
GAPDH      
(40´) 
phospho-IκB-α      
(5´) 
IκB-α      
(15´´) 
phospho-NF-κBp65 
(40´) 
NF-κBp65 
(40´) 
40 kDa  
 
40 kDa  
 
40 kDa  
 
37 kDa  
 
37 kDa  
 
80 kDa 
60 kDa  
 
80 kDa 
60 kDa  
 
50 kDa  
 
50 kDa  
 
67 
 
the untreated cells, the phosphorylated form of this protein was downregulated in all 
six breast cancer cell lines (see Figure 25). 
 
3.2.5 Quantitative analysis of MEK1/2 in untreated and Tpl2 
Kinase Inhibitor treated breast cancer cells 
In the non-canonical NF-κB pathway the Tpl2 kinase leads to an activation of MEK1. 
The following experiment was performed to verify if a downregulation of MEK1/2 
could be observed after the treatment with Tpl2 Kinase Inhibitor. 
 
 
 
 
 
          
 
 
Figure 31: Detection of MEK1/2 in untreated and Tpl2 Kinase Inhibitor treated breast cancer cells. 10 
µg of the cell lines (untreated and treated with 1 nM Tpl2 Kinase Inhibitor) were used for a 10% SDS-
Page gel and transferred onto a PVDF-membrane. The first antibody was diluted 1:1000 in 
SuperBlock Blocking Buffer. The Blots were incubated with Goat anti rabbit IgG (H+L) HRPO. As 
exposure time 30 minutes were chosen.  
 
The MEK1/2 expression in SKBR-3 and MCF-7 was downregulated after the 
treatment with Tpl2 Kinase Inhibitor. HCC-38 did not produce this protein in the naive 
state but seemed to gain this ability after treatment. The amount of MEK1/2 stayed 
the same in the other untreated and Tpl2 Kinase Inhibitor treated cell lines. 
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4 Discussion 
Given that BLBC is hardly sensitive to treatments usually administered in other types 
of breast cancer, there is urgent need for alternative therapeutic strategies. The main 
objective of my diploma work was to investigate novel experimental therapies for 
basal-like breast cancer based on inhibitors of signaling pathways.  
 
First of all, I investigated the MAPK pathway because it was known from literature, 
that EGFR is frequently overexpressed and that the transcription factor YB-1 is 
expressed in 73% of basal-like breast cancer cells (Stratford et al. 2008). 
Unexpectedly, none of the used inhibitors of the MAPK pathway, i.e. cetuximab, 
PD98059, U0126, ERK inhibitor II and III, and SL0101, was able to eradicate the 
investigated cancer cells (see Figures 11-12).  
Being much more efficient, a low IC50 value using MTT-assays could only be 
obtained by inhibition of the NF-κB pathway. With this strategy, several compounds 
were effective, such as disulfiram, Akt Inhibitor IV, violacein, BAY 11-7082, MG-132 
and Tpl2 Kinase Inhibitor (see Figures 14-19 and Tables 25-30). A marginally 
suppressive effect could be observed by inhibiting IGF1-R with PQ401 (data not 
shown). 
As there is currently no inhibitor of YB-1 available, this putatively relevant 
transcription factor could not be assessed by MTT-assays. To analyze the effect of 
other active inhibitors on the expression of YB-1, I investigated untreated cells and 
cells treated with disulfiram, Akt Inhibitor IV and violacein by Western blotting. The 
data showed that there is no difference in the expression of YB-1 in the untreated 
basal-like breast cancer cells compared with the untreated reference cells. Likewise, 
the level of RSK2, the precursor protein of YB-1, was almost the same in all six 
breast cancer cell lines (see Figure 21). Unfortunately, no informative results could 
be obtained for the activated form of this transcription factor, phospho-YB-1S102, due 
to technical problems in combination with unspecific binding of phospho-YB-1S102 
(see Figure 21). After the treatment with Akt Inhibitor IV less YB-1 was produced in 
all cells and the amount of RSK2 was not altered (see Figure 22). This result was 
expected insofar as it was known from literature, that phosphorylated Akt directly 
activates YB-1 (Stratford et al. 2008). Unfortunately, a statement with respect to the 
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activated form of this transcription factor, which might be an important one, is limited 
to the observation that the binding of phospho-YB-1S102 is very unspecific. However, 
with the generated data it can be shown that the treatment with the NF-κB pathway 
inhibitors has no impact on the amount YB-1 and RSK2 in the BLBC as well as in the 
reference cells (see Figures 23-24). 
As the next focus, cytotoxicity assays with combinations of two inhibitors or one 
inhibitor and one cytotoxic agent were performed to determine if an earlier inhibition 
of the cells could be reached with a combination of two substances. In fact, a lower 
IC50 value was only observed by combination of Akt Inhibitor IV and violacein when 
compared with the IC50 values of these two substances alone (see Figure 20). 
However, this effect was limited to the reference cell lines (MCF-7, SKBR-3, MDA-
MB-468), but was not observed in the basal-like breast cancer cells (HCC-38, HCC-
1937, MDA-MB-231) (see Figure 20). No increase in inhibition efficiency or a 
neutralizing effect could be obtained with all other tested 27 combinations. These 
combinations addressed single pathways by using two inhibitors within the pathway, 
the combination of two pathways by using two corresponding inhibitors or the 
combination of signaling inhibitors with cytotoxic agents (data not shown).  
Among the investigated signaling pathways believed to be essential for BLBC in vitro, 
it seemed that the NF-κB pathway is the only pathway which is needed for the 
survival of these cancer cells. Therefore, Western Blots were done to investigate the 
NF-κB pathway in detail. First of all the untreated cells were blotted with the 
antibodies IKK-α, IKK-β, phospho-IKK-α/β, NF-κBp65, phospho-NF-κBp65, IκB-α and 
phospho-IκB-α, which are all members of the canonical NF-κB pathway. In case of 
IKK-α, IKK-β and phospho-IKK-α/β no informative results could be obtained and 
therefore no statement about these proteins can be done (see Figure 25). However, 
basal-like breast cancer cells were overexpressing NF-κBp65 and the 
phosphorylated form of this protein as well. The cell lines HCC-38 and HCC-1937 
were producing more IκB-α, but all cell lines expressed the same amount of 
phospho-IκB-α (see Figure 25). These data show that the BLBC are more regulated 
by the canonical NF-κB pathway than the reference cells are. Further Immunoblots 
were done with the six cell lines treated with the inhibitors violacein, Tpl2 Kinase 
Inhibitor, MG-132, BAY 11-7082 and Akt Inhibitor IV. NF-κBp65 was downregulated 
in the violacein treated basal-like breast cancer cells. The phosphorylated form of this 
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protein was only suppressed in one BLBC (MDA-MB-231) and in one reference cell 
(MCF-7). The phospo-IκB-α was downregulated in all six cells whereas the 
unphosphorylated form was only inhibited in SKBR-3 and MDA-MB-231 (see Figure 
26). It is known that the pigment isolated from Chromobacterium violaceum inhibits 
the expression of the p65 subunit partially and the p50 subunit completely, but it is 
not known on which level this inhibition takes place. Further it is known that this 
substance inhibits the phosphorylation of IκB-α (Kodach 2006). The downregulation 
of phospho-IκB-α, which was observed in my experiment, was anticipated. However, 
it was not expected that the unphosphorylated form of this protein was suppressed in 
two cell lines as well, because violacein should not have an effect on this NF-κB 
pathway family member. A reason for the downregulation of NF-κBp65 but no 
alteration of the phosphorylated form, could be the fact that phospho-NF-κB cannot 
only be generated by the unphosphorylated form, but also by the Tpl2 kinase 
dependent pathway. In this pathway Tpl2 activates RSK1 via MEK1 and ERK1/2 and 
this protein phosphorylates free NF-κB. This transcription factor can bind the DNA in 
the nucleus in either phosphorylated or unphosphorylated state. My data suggest that 
after the treatment with violacein, less unphosphorylated NF-κB is binding the DNA. 
After treatment of the cells with Tpl2 Kinase Inhibitor the amount of NF-κBp65 was 
not altered. The phosphorylated transcription factor subunit was downregulated in 
one BLBC (MDA-MB-231) and in one reference line (MCF-7). An upregulation of this 
protein took place in the cell line MDA-MB-468 (see Figure 27). While no alteration in 
the NF-κBp65 levels was anticipated, it was unexpected that a downregulation of the 
phosphorylated form only took place in one BLBC and one reference cell instead of 
all six cell lines. It is known, that the Tpl2 Kinase Inhibitor suppresses the activation 
of MEK1 from Tpl2 (Gavrin et al. 2005). Therefore, phospho-NF-κB should normally 
not be generated via this pathway. This is why only the activated form of this 
transcription factor should be suppressed by this inhibitor. The amount of IκB-α was 
not altered by the treatment of the cells with Tpl2 Kinase Inhibitor. Phospho-IκB-α 
was downregulated in HCC-38 and MDA-MB-468 (see Figure 27). By current 
knowledge, one would not expect a modulation of phospho-IκB-α in these two cell 
lines as Tpl2 acts downstream of this protein. This hitherto unnoticed interaction 
might point at an interaction between the canonical and non-canonical NF-κB 
pathway which are not yet characterized at this level. 
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Except HCC-38, all cell lines treated with the proteasome inhibitor MG-132, were 
producing less NF-κBp65. Further all treated cells except MDA-MB-468 were 
expressing lower levels of the phosphorylated form of the protein. The phospho-IκB-α 
was downregulated after exposure to MG-132 in all cell lines and the 
unphosphorylated IκB-α was suppressed in five of the six breast cancer cells (see 
Figure 28). This proteasome inhibitor normally prevents the degradation of 
phosphorylated IκB-α and therefore the release of free NF-κB from the binding 
complex (Morelli et al. 2003). Concerning NF-κBp65, phosphorylated and 
unphosphorylated IκB-α, the data of this experiment were very surprising as one 
would expect either an increase of these proteins or at least no downregulation when 
compared with the cells without treatment with MG-132. Normally, more of the NF-
κB-IκB-α and NF-κB-phospho-IκB-α complexes should be present, if the degradation 
of phosphorylated IκB-α is prevented by this inhibitor, which was not the case. In 
contrast, the data obtained for phospho-NF-κBp65 were in agreement with the 
theory, because if no unphosphorylated NF-κB is released from the complex, no 
phosphorylation of this protein can take place via this canonical pathway. Thus, the 
proteasome inhibitor MG-132 has very likely some other effects, which are not yet 
known soliciting the need for detailed investigations on the comprehensive 
mechanism of action of this inhibitor. 
The substance BAY 11-7082 inhibits the phosphorylation of IκB-α (Scaife et al. 
2006). As for violacein a downregulation of phospho-NF-κB and phospho-IκB-α and 
no alteration in the amount of NF-κBp65 and IκB-α was expected. In contrast to my 
expectations, NF-κBp65 was suppressed in all basal-like breast cancer cells and in 
one reference cell line (MCF-7), while the other two reference cells were producing 
more of this protein. Furthermore phospho-NF-κB was downregulated in MDA-MB-
231, MCF-7 as well as SKBR-3 and upregulated in MDA-MB-468. The level of 
phospho-NF-κB stayed the same in HCC-38 and HCC-1937. No alteration in the 
amount of unphosphorylated and phosphorylated IκB-α could be detected in all cell 
lines (see Figure 29). Similar to observations reported above, an explanation for 
these unexpected results could be hitherto unknown interactions between pathways. 
For example, BAY 11-7082 may also have additional effects to the inhibition of the 
IκB-α phosphorylation.  
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The last inhibitor I used for treatment of the breast cancer cells was Akt Inhibitor IV. 
While NF-κBp65 was suppressed in the BLBC and MCF-7, SKBR-3 was producing 
more of this protein after the treatment with this substance. No alteration could be 
observed in the cell line MDA-MB-468. The production of phospho-NF-κBp65 was 
inhibited in all breast cancer cells, except in MDA- MB-468. The phosphorylated IκB-
α was downregulated in all six cell lines and less IκB-α was produced in all cancer 
cells, except in MDA-MB-468 (see Figure 30). Concerning the downregulation of 
phospho-IκB-α and phospho-NF-κBp65, these results were in accordance with my 
expectations. Normally, Akt Inhibitor IV prevents the phosphorylation of Akt, which 
directly activates the IKK complex (http://www.emdchemicals.com).  
MDA-MB-468 was not reacting as a basal-like cancer cell nor as a reference cell. 
This cell line is a basal-like breast cancer cell which is not triple negative. This seems 
to be the reason why the data of this cell line often did not match with the data of the 
real basal-like breast cancer cells or the reference breast cancer cells. 
According to the results of the Tpl2 Kinase Inhibitor in the cytotoxicity assays and the 
Immunoblotting (see Figures 19 and 27), it had to be investigated if this substance 
really prevents the production of MEK1. This was done by Western blotting with Tpl2 
Kinase Inhibitor treated cells in comparison to untreated cells. The antibodies used 
for these approaches detected unphosphorylated MEK1/2 and phospho-MEK1/2. 
Unfortunately the results for the phosphorylated form of this protein were not 
informative and therefore no statement in respect to the activated state of MEK1/2 
can be done (data not shown). However the amount of MEK1/2 was only 
downregulated in two reference cell lines (MCF-7 and SKBR-3). No alteration in the 
expression level of this protein could be observed in the other four cell lines (see 
Figure 31). Maybe the signal of MEK1 was masked by the signal of MEK2 in this 
experiment. Another explanation for these data is that MEK1 is not the only target 
from Tpl2. For detailed information of the Tpl2 kinase dependent NF-κB pathway 
more experiments would be useful. One possibility would be the use of MEK1 and 
MEK2 specific antibodies to be sure which subunit of the two MEKs is detected and 
to address possible differences between these subunits. 
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Conclusion 
After investigation of the MAPK pathway, the PI3K-Akt-mTOR pathway and the NF- 
κB pathway, as pathways known to be relevant for vital cellular functions, the NF-κB 
signaling pathway seems to be the most important one for the survival of the basal-
like breast cancer cells. Except disulfiram, all inhibitors of this pathway led either to a 
complete eradication or to a growth stop of the cells in the cytotoxicity assays at a 
low micromolar concentration (IC50: 0.01 µM – 3.4 µM). By Immunoblotting upon 
exposure with different NF-κB pathway inhibitors, it could further be shown that the 
canonical NF-κB pathway is very complex. Moreover, the obtained data suggest that 
interactions with other signaling pathways might take place, because some of the 
used substance did affect the canonical NF-κB pathway members in ways not in 
agreement with current knowledge. For detailed information about this pathway and 
the communication with other pathways more experiments are needed. No statement 
about the importance of the transcription factor YB-1 can be done by these 
experiments, because no informative results could be obtained for phospho-YB-1S102. 
Maybe the activated form of this protein plays a key role in the survival of the basal-
like breast cancer cells too, but a good working antibody would be needed for these 
approaches. It would be a very worthwhile endeavor to investigate if this transcription 
factor can not only be activated by the MAPK pathway and the PI3K-Akt-mTOR 
pathway, but also by the NF-κB signaling pathway. In conclusion, the results of these 
experiments lead to the assumption that alternative therapeutic strategies for basal-
like breast cancer should be based on NF-κB pathway inhibition. 
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6 Abbreviations 
´   minutes 
´´   seconds 
°C   degrees Celsius 
µg   microgram 
µl   microliter 
µM   micromolar 
AMP   adenosine monophosphate 
APS   ammonium peroxodisulfate 
ATCC   American type culture collection 
ATF-3   cyclic AMP dependent transcription factor 3 
ATP   adenosine triphosphate 
BAP1   BRCA-1 associated protein 1 
BLBC   basal-like breast cancer 
Bmi1   BMI1 polycomb ring finger oncogene 
BRCA-1  breast cancer antigen 1 
CD133  prominin 1  
CDC2   cyclin-dependent kinase 1 
c-Jun   jun proto-oncogene 
CK   cytokeratin 
c-kit   tyrosine kinase KIT 
c-myc   v-myc myelocytomatosis viral oncogene homolog (avian) 
cm2   square centimeter 
ddH2O  double distilled water  
DMSO  dimethyl sulfoxide 
DNA   deoxyribonucleic acid 
DTT   1,4 Dithiothreitol 
EDTA   ethylenediaminetetraacetic acid 
EGF   epidermal growth factor 
EGFR   epidermal growth factor receptor 
EGP2   epithelial glycoprotein 2 
Elk1   E twenty-six (ETS)-like transcription factor 1 
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ER   estrogen receptor 
ERK   extracellular signal-regulated kinase 
ext.   extinction 
FCS   fetal calf serum 
fos   FBJ murine osteosarcoma viral oncogene homolog 
g   gram 
GATA-3  GATA binding protein 3 
GDP   guanosine diphosphate 
GTP   guanosine-5'-triphosphate 
h   hours 
HE   hematoxylin 
Her2 (ErbB2) human epidermal growth factor receptor 2 
IC50   inhibitory concentration leading to 50% growth inhibition 
IGF1R  insulin-like growth factor 1 receptor 
IgG   immunglobulin G 
IκB   inhibitory kappa B protein 
IKK   IκB kinase complex 
JNK   c-Jun amino-terminal kinase 
kDa   kilodalton 
l   liter 
m   molar 
mA   milliampere 
MAD2   mitotic arrest deficient 2 
MAD2L1  MAD2 mitotic arrest deficient-like 1 (yeast) 
MAPK   mitogen activated protein kinase 
MAPKK  mitogen activated protein kinase kinase 
MAPKKK  mitogen activated protein kinase kinase kinase 
ml   milliliter 
mM   millimolar    
mTOR  mammalian target of rapamycin 
MTT   3-(4,5- Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NEMO  nuclear factor kappa B essential modulators 
NF-κB   nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
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nM   nanomolar 
nm   nanometer 
PBS   phosphate buffered saline 
PDK1   phosphoinositide-dependent kinase 1 
PI3K   phosphatidylinositol-3-kinase 
PIP3   phosphatidylinositol-3,4,5-triphosphate (PI(3,4,5)P3) 
PKB (Akt)  protein kinase B 
PKC   protein kinase C 
PR   progesterone receptor 
PTEN   tumor suppressor gene phosphatase and tensin homolog 
PVDF   polyvinylidene fluoride 
RAD21  RAD21 homolog (S.pombe) 
RHD   Rel homology domain 
RSK   p90 ribosomal S6 kinase 
RT   room temperature 
SDS   sodium dodecyl sulfate 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SLUG   snail homolog (Drosophila) 
Sox2   sex determining region Y - box 2  
TBS   tris buffered saline 
TGF   transforming growth factor 
tit.   titrated 
TNF   tumor necrosis factor 
TP53   tumor protein p53 
Tpl2   tumor progression locus 2 
VEGF   vascular endothelial growth factor 
YB-1   Y-box binding protein 1 
YB-1S102  Y-box binding protein 1 phosphorylated at serine 102 
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7 Abstract 
About 15% of all breast cancer cells are triple negative for the hormone receptors 
estrogen, progesterone and Her2/neu (human epidermal growth factor receptor 2). 
Almost all of these are basal-like breast cancer (BLBC) cells. As this subtype of 
mamma carcinoma cannot be treated with anti-estrogens or Her2 neutralizing 
antibodies, taxanes, antracyclines and platinum derivatives are currently tested in 
clinical trials. Inhibition of signaling pathways may offer another option in this 
aggressive subtype of breast cancer. 
To investigate which pathways play a key role for the cells, dose response curves 
(MTT-assay) with different inhibitors, cytotoxins and combinations of both were 
established. HCC-38, HCC-1937 and MDA-MB-231 were used as representative 
BLBC cells with epithelial or luminal breast cancer cells as reference (MCF-7, SKBR-
3 and MDA-MB-468). The following inhibitors were used: cetuximab (against EGFR), 
PD98059 and U0126 (against MEK1/2), ERK Inhibitor II (against ERK1/2), ERK 
Inhibitor III and SL0101 (against RSK), Akt Inhibitor IV (against Akt), wortmannin 
(against PI3K), rapamycin (against mTOR), PQ401 (against IGF1R), violacein, 
disulfiram, MG-132, Tpl2 Kinase Inhibitor and BAY11-7082 (all NF-κB inhibitors). The 
MTT-assays showed that the inhibition of NF-κB strongly inhibited the BLBC cells. 
Quantitative analysis of the canonical NF-κB pathway members (IKKα, IKKβ, 
phospho-IKKα/β, NF-κBp65, phospho-NF-κBp65, IκB-α and phospho-IκB-α) were 
done with lysates of the inhibited cells by Immunoblotting. The blotting of the 
untreated cells showed that the basal-like cells were overexpressing NF-κBp65 and 
phospho-NF-κBp65 compared with the reference cells. The expression of NF-κBp65 
was downregulated in BLBC after treatment with violacein, MG-132, BAY11-7082 
and Akt Inhibitor IV. Phospho-NF-κBp65 did not show consistent results in the BLBC 
cells. The IKK proteins were below the detection limit of the Western blot. IκB-α and 
phospho-IκB-α were downregulated in almost all cells after the treatment with 
violacein, MG-132 and Akt Inhibitor IV.  
These data show that the NF-κB pathway is an important signaling pathway for the 
survival of the basal-like breast cancer cells. In response to the tested inhibitors, the 
regulation of this pathway seems to be very complex suggesting a communication 
between the canonical NF-κB pathway and other signaling pathways as MG-132, 
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Tpl2 Kinase Inhibitor and BAY11-7082 did not downregulate their target proteins as 
expected. All used NF-κB inhibitors, except disulfiram, were effective in the MTT-
assays resulting either in complete eradication or growth stop of the cells (IC50: 0.01 
µM – 3.4 µM). In conclusion, these experiments show that alternative therapies for 
basal-like breast cancer based on the NF-κB pathway may be a promising approach.  
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8 Zusammenfassung 
Ungefähr 15% aller Brustkrebszellen sind dreifach negativ für die Hormonrezeptoren 
Östrogen, Progesteron und Her2/neu (human epidermal growth factor receptor 2). 
Fast alle von diesen sind Mammakarzinome vom Basaltyp (BLBC). Da dieser 
Brustkrebssubtyp nicht mit Antiöstrogenen oder Her2 neutralisierenden Antikörpern 
behandelt werden kann, werden Taxane, Antrazykline und Platinderivate im Moment 
in klinischen Studien getestet. Eine andere Möglichkeit der Therapie dieses 
aggressiven Subtyps, könnte die Inhibierung verschiedener Signalwege darstellen. 
Um herauszufinden welche Signalwege eine Schlüsselrolle für diese Zellen spielen, 
wurden Dosis-Wirkungskurven (MTT-Assay) mit verschiedenen Inhibitoren, 
Zytotoxinen und Kombinationen beider erstellt. HCC-38, HCC-1937 und MDA-MB-
231 wurden als repräsentative Brustkrebszellen des Basaltyps herangezogen. 
Epitheliale oder luminale Mammakarzinome (MCF-7, SKBR-3 und MDA-MB-468) 
dienten als Referenzzellen. Folgende Inhibitoren wurden für die Experimente 
verwendet: cetuximab (gegen EGFR), PD98059 und U0126 (gegen MEK1/2), ERK 
Inhibitor II (gegen ERK1/2), ERK Inhibitor III und SL0101 (gegen RSK), Akt Inhibitor 
IV (gegen Akt), wortmannin (gegenPI3K), rapamycin (gegen mTOR), PQ401 (gegen 
IGF1R), violacein, disulfiram, MG-132, Tpl2 Kinase Inhibitor und BAY11-7082 (alle 
NF-κB Inhibitoren). Mittels der Dosis-Wirkungskurven konnte gezeigt werden, dass 
die Inhibierung von NF-κB das Überleben der BLBC verhindert. Eine quantitative 
Analyse der kanonischen NF-κB Signalwegmitglieder (IKKα, IKKβ, phospho-IKKα/β, 
NF-κBp65, phospho-NF-κBp65, IκB-α und phospho-IκB-α) wurde mit Lysaten der 
inhibierten Zellen mittels Immunoblotting erreicht. Es konnte gezeigt werden, dass 
die unbehandelten Basalzellen die Proteine NF-κBp65 und phospho-NF-κBp65 im 
Vergleich zu den Referenzzellen überexpremieren. NF-κBp65 wurde durch die 
Behandlung der Zellen mit violacein, MG-132, BAY 11-7082 und Akt Inhibitor IV 
runterreguliert. Phospho-NF-κBp65 reagierte nach der Behandlung mit den 
Substanzen in den Zelllinien nicht immer gleich. Über die IKK Proteine konnte keine 
Aussage getroffen werden, da sie unter dem Detektionslimit lagen. Die Expression 
von IκB-α und phospho-IκB- α wurde nach der Behandlung mit violacein, MG-132 
und Akt Inhibitor IV in fast allen Zellen verringert. 
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Diese Ergebnisse zeigen, dass der NF-κB Signalweg einen wichtigen Weg für das 
Überleben der Basalzellen darstellt. Die Regulation dieses Signalweges scheint sehr 
kompliziert zu sein und es liegt die Vermutung nahe, dass es eine Kommunikation 
zwischen dem kanonischen NF-κB Signalweg und anderen Signalwegen gibt, da 
manche verwendeten Substanzen (MG-132, Tpl2 Kinase Inhibitor und BAY 11-7082) 
nicht immer in der Lage waren die betreffenden Proteine zu inhibieren. Alle 
verwendeten Inhibitoren, außer Disulfiram, haben bei den MTT- Experimenten 
entweder zu einem Wachstumsstopp oder zu einer Eradikation der Zellen geführt 
(IC50: 0,01 µM – 3,4 µM). Zusammenfassend kann gesagt werden, dass es 
vielversprechend scheint, alternative Therapien für das Mammakarzinom vom 
Basaltyp auf dem NF-κB Signalweg basieren zu lassen. 
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